Synthesis of 9-Substituted-8-oxoadenines as Potential Inhibitors of DNA Repair Enzymes in Cancer Therapy by Siah, Huey  San Melanie
  
Thesis for the Master’s Degree in 
Chemistry 
Huey-San Melanie Siah 
 
Synthesis of 9-Substituted-8-
oxoadenines as Potential Inhibitors 
of DNA Repair Enzymes in Cancer 
Therapy 
60 study points 
DEPARTMENT OF CHEMISTRY 
Faculty of Mathematics and  
Natural Sciences 
University of Oslo, June 2011 
 
ii 
 
iii 
 
ACKNOWLEDGEMENTS 
First and foremost, I would like to thank my advisor, Professor Lise-Lotte Gundersen, for her 
invaluable guidance on this project and dedication to the members of our group. Secondly, I 
thank Bjørn Dalhus for his collaboration on this project and carrying out the biological 
testing. 
To the fantastic gentlemen at both the NMR and MS labs – especially one Professor Frode 
Rise – this project would not be possible without your very much appreciated hard-work and 
fabulous instruments! 
A big thanks goes out to the lovely people of the Gundersen group. There is not much that I 
know about practical chemistry that has not come from you guys. In addition, an extra thank 
you must go to Matty, Abhi and Heidi for always entertaining me when I enter their offices 
saying, “I have a question…” 
Thanks goes to our fellow chemists on the 3
rd
 floor – especially Kim, Marte, Eirin, Benji and 
Christian – who are always welcoming when I have needed inspiration or just a coffee break. 
Chemistry is cool! And I believe I speak for many of us on the 2
nd
 and 3
rd
 floors when I thank 
SMN for buying us a coffee machine and supplying us with beans! 
Thank you to Hege for the many hours of exam-study, language assistance and 
procrastination, and for always helping me to clean my hood when I have an “accident”. To 
Suzanne, thanks for making me laugh, both in the lab and when we go skiing. I love you, 
man! 
To future Masters students, I can recommend Matty, Heidi, Kim, Hege and my sister, 
Melissa, as excellent proofreaders, if you can catch them while they are running around doing 
the thousand things they have on at any given time. 
Thank you to my family for encouraging me to fulfil my potential both in the academic and 
extra-curricular fields from a very young age. Finally, I would be nowhere – especially not in 
Norway – without the love and support of my husband, Anders, who lets me ramble about 
chemistry despite only understanding every third word and gave me a periodic table shower 
curtain for my birthday. 
iv 
 
v 
 
ABSTRACT 
Cancer is a well-known group of diseases with a plethora of available treatments that have 
varying side-effects and patient survival rates. One aspect of cancer treatment that has not 
been investigated in depth is the possibility of inhibiting enzymatic cell repair to increase 
cancer cell death and dormancy due to chemotherapy and radiation therapy.  
The 7,8-dihydro-8-oxoguanine (1) and the 7,8-dihydro-8-oxoadenine (2) lesions (shown 
below in Figure 1) are modified DNA bases that have been oxidised by reactive oxygen 
species (ROS), for example through cancer treatment, and have been identified has having 
high mutagenic potential and therefore suitable to cause dormancy or death of cancer cells.
1-3
  
 
Figure 1. 7,8-dihydro-8-oxoguanine (1) and the 7,8-dihydro-8-oxoadenine (2) lesions, attached at N-9 
to the sugar and phosphate backbone in DNA. 
This project has focused on the synthesis of 9-substiuted-8-oxoadenines (3) as potential 
inhibitors (Figure 2), and this has required the use of several different strategies. In addition, 
some attention has been given to the possibilities of functionalising the C-8 position on the 
purine ring as part on an ongoing project in the Gundersen group at UiO. 
 
Figure 2. General structure of target molecules. 
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CHAPTER 1 
1.  BIOLOGICAL BACKGROUND 
1.1. General 
In Norway alone, there were 26,121 new cases of cancer registered at Kreftregisteret (“the 
Cancer Registry”) in 2008, with prostate, female breast, colon and lung cancers being the 
most common types reported.
4
 The World Health Organisation (WHO) reports that every year 
at least 7 million people die of cancer. Half of these deaths are avoidable, and mortality rates 
are higher in developing countries due to a lack of access to medical technology and 
treatment.
5
 Although there already exists a wide range of treatments for different types of 
cancer, there is still room for improvement of survival rates, especially for certain types of 
cancer.
6
  
Two types of established treatments directly cause damage to cancerous cells – radiation 
therapy (using ionizing radiation) and chemotherapy (treatment with drugs). A third common 
treatment is surgery to remove the cancerous cells. Both radiation therapy and chemotherapy 
cause damage to the DNA of cancer cells with the aim of causing cell dormancy or death in 
order to eliminate cancers completely or cause them to become benign. However, DNA repair 
mechanisms in cancer cells can inhibit the effectiveness of such methods by healing the 
damaged DNA in these cells.
6
 There exists some research in this area, but there is still a need 
for further research targeting specific repair mechanisms to improve already established 
treatments – i.e. development of inhibitors of proteins that carry out DNA repair.6 
The targeting of potential protein inhibitors is based on the principle that cancer cells will be 
affected by DNA damage more than normal cells due to the high rate of cell division and 
metabolism in the former. This could potentially result in higher rates of mutation, cell death 
and/or dormancy in the more active cancer cells. The current project has involved synthesis of 
target molecules that are intended to act as inhibitors for certain DNA glycosylases – human 
alkyladenine DNA glycosylase (hAAG) or human 8-hydroxyguanine DNA glycosylase 
(hOOG1); the former partakes in BER of alkylated adenines and the latter partakes in BER of 
8-oxoguanine lesions.
7,8
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1.2. DNA Replication, Damage and Repair 
1.2.1. DNA Replication 
When cells reproduce, one important step of the cell cycle is DNA replication in preparation 
for cell division (mitosis). This process is complicated, involving many different proteins. 
One of these proteins causes the breaking of the hydrogen bonds between the bases in the 
DNA double helix at particular points known as “origins”. Other proteins hold the unwound 
DNA strands in place creating a “bubble” in the DNA, resulting in the creation of two 
“replication forks”. Each strand of DNA is then used as a template for the assembly of a new 
complementary strand by pairing the bases in the new strand with those in the template strand 
(Figure 3 and Figure 4).
9
  
 
Figure 3. Diagram showing the major steps of initiating replication forks at replication origins and the 
use of the original DNA strands as templates for the new strands.
9
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Figure 4. In DNA, nucleotides will only pair with one other nucleotide (i.e. form a “base-pair”). For 
example, adenine (A) will only pair with thymine (T), while guanine (G) will only pair with cytosine 
(C) because of the specific pattern of hydrogen-bonds between the nucleotides (left) – meaning that 
each strand of DNA can serve as a template to specify the sequence of nucleotides in its 
complementary strand by DNA base-pairing (right).
9
   
1.2.2. DNA Damage 
There are many kinds of damage that can occur in human DNA that result in the improper 
function or death of cells, such as base modifications, single-strand breaks and double-strand 
breaks, replication lesions and DNA crosslinks.
10
 These types of modifications to DNA, when 
uncorrected, can lead to events such as the deletion of a base pair or base-pair substitution in 
the strands during the replication process, which can cause problems in the cell cycle or 
mutations to the cell’s DNA, resulting ultimately in cell death or dormancy.  
Healthy cells and cancer cells have different properties, one of which is that cancer cells have 
a higher rate of cell division and metabolism.
10
 Cancer treatments take advantage of this 
difference by causing DNA damage to all cells, but that affects cancer cells to a greater extent 
4 
 
to preferentially provoke cell death or dormancy in those cells.
9-11
 In the current project, the 
targeted enzymes are known to carry out repair of alkylated adenine bases and oxidised 
guanine bases (base damage). They are also believed to repair other types of DNA 
damage.
12,13
 In this section, we will have a look at the causes and repair of damaged bases. 
In Figure 5 below are shown the bases found in DNA – guanine, cytosine, thymine and 
adenine – attached to their sugar moieties and phosphorous backbone. Shown with arrows are 
the sites where spontaneous damage can occur (see Figure 5).
9,14
 In addition, DNA base 
modifications can be induced by oxidation, deamination, alkylation or the addition of bulky 
adducts to these bases through cancer treatments.
15
 Examples of alkylating agents that are 
used in chemotherapy are shown in Figure 6.
10
  
 
Figure 5. The sites on each nucleotide that are known to be modified by spontaneous oxidative 
damage (red arrows), hydrolytic attack (blue arrows), and uncontrolled methylation by the methyl 
group donor S-adenosylmethionine (green arrows) are shown, with the width of each arrow indicating 
the relative frequency of each event.
9,14
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Figure 6. Examples of alkylating agents used in chemotherapy.
16
  
One problem with radiation therapy and chemotherapy is that some of the damage inflicted on 
DNA is countered by DNA repair enzymes which repair damage caused by cancer therapy 
and reduce their effectiveness. In healthy cells, DNA repair mechanisms are essential for 
maintaining the structural integrity of DNA. However, in cancer cells, it is an unwanted 
hindrance to the effectiveness of the cancer treatment.  
The hypothesis behind the current project is that inhibition of repair mechanisms will also 
take advantage of the differences between healthy cells and cancer cells and enhance the 
effect of cancer treatments on the latter. This idea has received some attention previously with 
respect to several repair proteins, but there remain many possibilities for new developments.
10
 
In Figure 7 below, proteins that have already been targeted for inhibition in order to enhance 
cancer treatment are shown in blue. 
6 
 
 
Figure 7. An overview of mammalian DNA repair pathways (not including all involved proteins). A 
blue background indicates proteins that are emerging as strong lead targets for cancer therapeutics and 
a red circle indicates that some data has been obtained.
6
 
1.2.2.1. Direct Repair of Base Damage 
Direct repair or direct reversal of DNA damage is a relatively easy mechanism and is 
undertaken by the AlkB enzymes and O
6
-alkylguanine DNA methyltransferase (AGT) 
protein.
17
 AGT transfers an alkyl group from an alkylated lesion on a DNA base to an active 
cysteine site. The AGT protein is consumed in the mechanism and thus would be more 
amenable to inhibition than a catalytic enzyme (Scheme 1).
18
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Scheme 1. Mechanism of the direct repair of an alkylated guanine (21a) by AGT.
18
  
The AlkB enzymes carry out the same procedure through an alternative oxidative dealkylation 
process. Inhibition of these mechanisms are favourable in combination with alkylating agents 
used in chemotherapies such as alkyl sulfonates, nitrosourea compounds, temozolomide, 
nitrogen mustard, Mitomycin C and Cisplatin (see Figure 6 above).
10
 
AGT was one of the first DNA repair targets identified for inhibition.
6
 O
6
-Benzylguanine 
(BG) (Figure 8) has been shown to be a potent inhibitor of AGT and increases the potency of 
chloroethylating and methylating agents. BG binds to AGT and transfers a benzyl group to the 
active cysteine site of the protein, effectively “killing” the protein.19 
 
Figure 8. Structure of AGT inhibitor, O
6
-benzylguanine (21b). 
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1.2.2.2. Base Excision Repair of Base Damage 
When damage to a base occurs, the most common mechanism for repair is through BER, 
which repairs DNA bases that have been damaged through oxidation, alkylation, hydrolysis, 
or deamination. A family of enzymes known as DNA glycosylases are responsible for 
identifying and excising specific lesion bases, such as 8-oxoadenine, from the strand,
8
 and the 
enzymes targeted in the current project belong to this family.  
After excision, a non-basic site is left at the point of excision and PARP proteins indicate to 
other proteins where a DNA strand break exists so that these proteins can carry out the actual 
reparation.
6
 The enzyme Apurinic endonuclease 1/Redox factor-1 (APE1/Ref-1) and 
subsequently enzymes β-polymerase and DNA Ligase III/XRCC1 then restore the site by 
reinstating the base moiety.
6
 There are thus several steps at which BER can be inhibited.  
Inhibition of the action of PARP proteins can make cancer treatments more effective, as a 
failure to recognise strand breaks and signal the repair proteins to act results in a 
dysfunctional BER mechanism.
20
 Several PARP inhibitors have been developed based on the 
biologically-produced nicotinamide and the compound 3-aminobenzamide. These inhibitors 
are usually monoaryl amides or cyclic amides with one or more rings (see e.g. Figure 9). They 
act competitively by blocking access to the catalytic part of the enzyme or blocking the 
attachment of the enzyme to DNA.
21
  
 
Figure 9. Examples of PARP inhibitors – KU-0059436 (22) 22 and ABT-888 (23) 23. 
Several compounds have been reported as inhibitors for APE1/Ref1 and these improve the 
toxicity of the chemotherapy drug temozolomide (Figure 6, Compound 11) in certain types of 
9 
 
cancer. One of these compounds, methoxyamine, binds to the sugar in the abasic site left from 
the excision preventing the action of APE1/Ref1 and subsequent proteins.
6
  
1.2.3.1.3. Nucleotide Excision Repair and Mismatch Repair of Base Damage 
NER and MMR are ways in which damage that affects the overall structure of DNA (e.g. 
cross-link damage) can be repaired.
6
 Nucleotide excision repair (NER) is important for the 
repair of large bulky lesions that distort the helix structure. The dual incision mechanism 
requires a large number of proteins that recognise, excise and replace a large part of the strand 
containing the lesion. The bulky lesion is first recognised by a group of proteins and a small 
opening may be created at this stage. The structure is then opened further by another protein 
and two structure-specific endonucleases are involved in the dual incision which removes the 
damage in a long strand. Repair synthesis is then carried out to repair the patch by a DNA 
ligase.
24
 
Mismatching of nucleotides, such as base substitution mismatches and insertion-deletion 
mismatches, can arise during DNA synthesis and requires repair in order to avoid fixed 
mutations – where the mismatched base becomes established in the DNA sequence. Mismatch 
repair (MMR) is similar to NER in that several proteins work together to identify the 
mismatch, excise a long single strand around the mismatch and to patch up the remaining 
DNA, but different proteins are involved.  
One inhibitor of NER is Fludarabine, an adenine-derivative that has been shown to be 
effective in the treatment of chronic lymphocytic leukaemia (Figure 10). This compound has 
proved to provoke a higher response rates to cancer therapy use of alkylating agents alone.
25
 
 
Figure 10. Structure of NER inhibitor, Fludarabine (24). 
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1.3. Choice of Target Molecules 
Although research on some of the many proteins involved in repairing DNA damage is being 
carried out, there is still much room for investigating and developing substances that will 
inhibit the action of repair proteins and sensitize cells to the effects of anti-cancer treatment.   
The design of the target molecules has been carried out in collaboration with Research Fellow 
Bjørn Dalhus at the Institute for Clinical Biochemistry at the Rikshospitalet-Radiumhospitalet 
Medical Centre. The initial in vitro biological testing is taking place at that institute, and the 
results that have been obtained so far are included in the thesis and further testing is planned 
for our compounds. 
The main aim of the current project was to synthesise molecules that have the potential to 
inhibit BER at the first stage – i.e. interfere with the action of DNA repair glycosylases that 
recognise and excise 8-oxoadenine lesions (3e) (Scheme 2). Target molecules were therefore 
designed to mimic the form of this oxidative lesion.  
 
Scheme 2. Oxidative lesion created by oxidation of the adenine moiety (7e) in DNA. 
The target molecules in this project have the aim of inhibiting the action of repair enzyme by 
being similar in the structure of 8-oxoadenine lesions (2) such that they will potentially 
interfere with the action of glycosylase enzymes. Target molecules are therefore 8-oxoadenine 
derivatives with different substituents attached to N-9. 
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The following molecules were targets for this project (see Figure 11): 
 6-amino-9-benzyl-7H-purin-8(9H)-one (3a) 
 6-amino-9-cyclopentyl-7H-purin-8(9H)-one (3b) 
 6-amino-9-(cyclohexyl)methyl-7H-purin-8(9H)-one (3c) 
 6-amino-9-phenyl-7H-purin-8(9H)-one (3d) 
 
Figure 11. The target molecules for the current project. 
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CHAPTER 2 
2. INTRODUCTION TO THE CHEMISTRY  
2.1. General  
The methods encountered in the course of the work done during the current project were N-
alkylation and N-arylation, nucleophilic aromatic substitution, lithiation, bromination, ring-
closing and hydrolysis. As will be shown in the thesis, the order in which these 
transformations are carried out has ramifications for yields, regioselectivity and can affect the 
difficulty of purification. 
In the current thesis, the standard International Union of Pure and Applied Chemistry 
(IUPAC) numbering system that is used for pyrimidine, imidazole and purine will be 
employed (see Figure 12).
26,27
 IUPAC names will also be given for each compound, but 
where appropriate a simplified version may be used to allow for ease of reading. 
 
Figure 12. Customary numbering system for pyrimidines, imidazoles and purines. 
Purines and pyrimidines are amenable to a wide variety of chemistry including reactions with 
nucleophiles, electrophiles and alkylating agents, in addition to, coupling reactions and 
halogenation.  
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2.2. Nucleophilic and Electrophilic Substitutions with Purine, Pyrimidine 
and Imidazole 
Diazines, including pyrimidine and imidazole, contain two nitrogen atoms, hence the name. 
These types of ring systems are more electron-poor than, for example, pyridine or benzene 
rings, due to the presence of electron-withdrawing nitrogen atoms in the former. As a result, 
nucleophilic attack on carbon atoms in the ring is easily carried out and electrophilic attacks 
are much more difficult than for pyridine or benzene.
28
 
The presence of a halogen on the position α to a ring-nitrogen of any hetroaromatic compound 
will increase the ease of nucleophilic attack at that position by decreasing the electron-density 
on the carbon to which it is attached, compared to having a hydrogen atom in the same 
position. These types of reactions involving 2-, 6- and 8-halopurines and 4- and  
6-halopyrimidines with nucleophiles are of vital importance to the synthesis of functionalised 
purines.
28-30
 For example, a fluoro, chloro or bromo group will activate its neighbouring 
carbon for SNAr attack while a bromo or iodo group can be useful in coupling reactions 
because of their weaker carbon-halogen bond, which allows for easier insertion of the 
catalytic metal species.
28
 
Nucleophilic attack on halogenated aromatic compounds, where a nucleophile is substituted 
with a halogen, does not undergo an SN1-type reaction due to the dissociation of the aryl 
halide being energetically unfavourable. Neither does it undergo an SN2-type reaction as it is 
sterically shielded from backside attack. This type of reaction, nucleophilic aromatic 
substitution (SNAr), occurs rather through a addition/elimination mechanism where the 
nucleophile attacks the aromatic ring to give a stabilised carbanion intermediate which then 
regains aromaticity through the elimination of chloride (Scheme 3).
31
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Scheme 3. Mechanism of SNAr on 4-chloropyrimidine (25a) to a 4-substituted product (25b). 
Imidazole is a more electron-rich ring system than pyrimidine because it is a six-electron 
aromatic system spread over only five atoms.
28
 This ring is thus able to react with 
electrophiles, as well as still being reasonably open to nucleophilic attack. The former 
includes reactions with alkylating and acylating agents on nitrogen and halogenation on 
carbon (Scheme 4). The latter is possible because the intermediate of nucleophilic attack on 
any halogenated carbon (preferably C-2) can also be resonance-stabilised onto the 
neighbouring nitrogen atoms (N-1 and N-3), similar to the case of pyrimidine (Scheme 3).
28
 
 
Scheme 4. Mechanism of a reaction of imidazole (26) with an electrophile (e.g. alkyl or acyl halide). 
15 
 
Purines consist of a fused-ring system that displays a combination of the characteristics of 
pyrimidine and those of imidazole. Nucleophilic aromatic substitutions are possible on 
carbons in both rings, although the reactivity of each position is dependent on substituent-
effects. However, reactions of purines with electrophilic reagents (e.g. halogenation reactions) 
on carbon only occur in the imidazole ring (in other words, on C-8).
28
  
2.3. N-Alkylation of Purines 
One of the challenges with N-alkylation of purines is that purines can exist in several 
tautomeric forms in both neutral and basic conditions (see Figure 13), resulting in the 
possibility of several regioisomeric products being produced in any single reaction. According 
to literature,
28
 the 7H and 9H tautomers are present in equal amounts in solution and the other 
two tautomeric forms are not present in significant amounts, but the distribution of the 
tautomers is dependent on both solvent effects and temperature and can also vary depending 
on the alkylating agent.
32,33
 
 
Figure 13. Tautomeric forms of purine (27) under neutral conditions and resonance forms under basic 
conditions. 
The conditions of the alkylation can play a large part in determining the result – including the 
type of base used, temperature and type of alkylating agent. For example, reaction of adenine 
with an alkyl halide in neutral conditions gives 9-alkylated (7) and 3-alkylated (28) adenine 
while in the presence of a base is reported to give mainly substitution on N-9 with the  
7-alkylated isomer (29) being an additional (minor) product in most cases.
28,34-36
 The  
16 
 
1-regioisomer has not been reported to be formed. It has been suggested that ratio of the 
regioisomers is dependent on the transition state of the particular reaction.
33
  
The general mechanism for deprotonation with a base, followed by nucleophilic attack on an 
alkyl halide is shown below (Scheme 5). 
 
Scheme 5. Scheme for deprotonation and attack of the anion on an electrophile. 
Alkylation of 8-bromoadenine in the presence of a base has been reported to give only  
9-subsituted products.
34,37
 
2.4. N-Arylation of Purines 
N-Arylation of adenine requires the creation of a carbon-nitrogen bond between two aromatic 
rings. Copper-mediated cross-coupling reactions between heteroatoms (C-N or C-O) using 
boronic acids have been discovered to be a mild, efficient and versatile method (Chan-Lam-
Evans coupling) and have the advantage of tolerating both air and room temperatures.
38-40
  
17 
 
There are literally hundreds of boronic acids commercially available so this type of reaction 
has many potential uses in the functionalization of purines.
40
 To the best of our knowledge, 
palladium-catalysed or nickel-catalysed coupling of an aryl boronic acid or aryl halide to a 
ring-nitrogen on a purine has not been reported, however, C-C coupling has been observed.
41
   
Arylation has been reported to occur regioselectively on the N-9 position of adenine,  
6-chloropurine and 2,6-dichloropurine using phenyl boronic acid in the presence of copper(II) 
acetate and a base (Scheme 6).
42-44
.  
 
Scheme 6. Chan-Lam-Evans coupling reactions on adenine (4), 6-chloropurine (13) and 2,6-
dichloropurine (13a)  using copper(II) acetate and phenyl boronic acid to give the arylated compounds. 
In the case of 8-bromoadenine (5), arylation has been reported to be less selective with both 
9- and 3-arylated compounds (6d and 30d) being produced, and the latter regioisomer as the 
major product.
42,45
 This regioselectivity may be due to either electronic or steric effects of the 
bromine substituent on C-8. 
 
Scheme 7. Chan-Lam-Evans coupling reactions on 8-bromoadenine (5).
42
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The mechanism for this copper-mediated coupling reaction (C-N bond forming) is not as 
well-established as that for palladium-coupling reactions (C-C bond forming). Scheme 8 
below depicts the routes through which copper-mediated coupling reactions with 
stoichiometric amounts of copper is thought to occur between a secondary amine and an aryl 
boronic acid.
40,46
 This mechanism may be, however, relevant for all N-arylations of 
heterocyclic compounds using boronic acid.  
 
 
 
 
 
 
 
 
Scheme 8. Mechanism describing Chan-Lam-Evans copper-mediated cross-coupling between an 
amine and aryl boronic acids and possible ligands.
40,46
 
 
19 
 
The mechanism begins with deprotonation of the amine and co-ordination to the copper 
complex by exchange of one acetate unit with the substrate. This results in rapid dissolution 
of the copper(II) acetate, which is insoluble in dichloromethane – the preferred solvent in 
these reactions following a solvent study of N-arylation of morpholine.
40
 Transmetallation of 
the arylboronic acid with the complex is the next step resulting in the purine-aryl-copper(II) 
complex which can undergo reductive elimination to the coupled product and copper(0). 
However, this step is very slow as the heterocycle binds tightly to copper. Thus, there is a 
high probability that the copper(II) complex is first oxidised by elemental oxygen in the air to 
a copper(III) complex with undergoes a much faster reduction/elimination reaction to give 
copper(I) and the desired product.
40
 The copper(I) can then be easily oxidised to regenerate 
copper(II) and complete the cycle. The reaction is thus facilitated by oxygen at two stages and 
it is not only convenient that this reaction tolerates air but benefits from an open reaction 
vessel.
40
 
2.5. Halogenation of Purines 
Three methods of bromination of purine substrates were encountered in the course of the 
current project. These were: 
 Bromination with liquid bromine (both in the presence and absence of water)  
 Bromination with N-bromosuccinimide  
 Halogenation via lithiation with lithium diisopropylamide and subsequent capture with 
a source of electrophilic halogen 
2.5.1. Bromination with Liquid Bromine  
Bromination with liquid bromine is suggested to involve addition of bromine across the 
imidazole double-bond followed by elimination of hydrogen bromide (Scheme 9).
28
 Purine 
itself does not undergo bromination on carbon, but adenosine derivatives undergo 
fluorination, chlorination and bromination at C-8. The proposed mechanism, shown with 
bromine in this example, follows the usual steps of electrophilic aromatic substitution 
(Scheme 9).
28
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The mechanism involves electrophilic attack by, most probably, the lone electron pair on N-7 
on bromine creating the N-bromopurinium salt (31a). This salt can undergo nucleophilic 
addition of the free bromide anion, followed by elimination of hydrogen bromide to give the 
brominated product (6).
28
 It is possible that the driving force in this last step could be the 
regaining of aromaticity in the imidazole ring. 
 
Scheme 9. Mechanism of bromination of 9-substituted adenines (7) through electrophilic attack on 
bromine and elimination of hydrogen bromide to give the 8-brominated product (6). 
2.5.2. Bromination with N-Bromosuccinimide 
N-Bromosuccinimide (NBS) is a brominating agent that can promote reactions via two 
different reaction mechanisms – through radical reactions and also electrophilic addition 
(Scheme 10).
47,48
 NBS is known to brominate allylic positions through the radical route in the 
presence of a radical initiator (Wohl-Ziegler reaction). In the absence of such an initiator 
and/or where an electron-rich substrate is used, NBS is a convenient source of what can be 
considered to be cationic bromine for electrophilic substitution reactions.
48
 
The mechanism below, bromination of 9-substituted purines with NBS, is an example of the 
latter route. NBS provides an electrophilic source of bromine to the reaction because the 
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strongly electron-withdrawing succinimide group pulls electron-density from the bromine 
atom, creating a partial positive charge on the halogen atom. This leaves the bromine 
vulnerable to attack by the nucleophilic purine, which results in an electrophilic addition of 
the purine. Removal of a proton by the succinimide anion gives the re-aromatised product.
47
 
The reaction is regioselective for the C-8 position because the imidazole-ring is electron-rich 
while the pyrimidine ring is electron-poor. 
Scheme 10. Mechanism of bromination of compounds 8 with NBS to give compounds 6 and 
succinimide (32). 
2.5.3. Lithiation and Capture with an Electrophilic Source of Bromine 
Halogenation using LDA involves deprotonation at C-8 and the formation of a lithiated 
species, followed by capture by an appropriate electrophile. This method has been employed 
extensively in the Gundersen group at UiO, and has been shown to be efficient on 9-benzyl-6-
chloropurines, with certain substituents on the benzyl ring, and has had some success on a 
limited range of 9-substituted adenines.
49
 
Scheme 11 shows the deprotonation of 9-substituted adenines (7) and creation of a lithium 
salt using lithium diisopropylamide (LDA). As adenines have an amino group which has a 
relatively acidic proton, this proton is deprotonated first followed by the deprotonation of the 
C-8 hydrogen, resulting in a dilithiated adenine salt.
50
 The presence of this amino group 
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therefore means that more of the base is required to deprotonate at C-8, than if it had not been 
present. 
 
Scheme 11. Mechanism for deprotonation of compounds 7 and subsequent capture with 1,2-dibromo-
1,1,2,2-tetrachloroethane to give compounds 6. 
The negative charge on the N
6
 can be delocalised into the pyrimidine ring giving conjugated 
tautomers. This is not the case for the negative charge on the C-8 carbon, which is unable to 
be stabilised by resonance. In addition, the five-membered imidazole ring is more electron-
rich than that six-membered ring. These factors result in the increased nucleophilicity and 
reactivity of C-8 compared with the deprotonated amino group (N
6
). This difference in 
reactivity is thought to be the basis of the regioselectivity of the method. Treatment of the 
lithiated species with, for example, 1,2-dibromo-1,1,2,2-tetrachloroethane molecule results in 
the 8-brominated product.
51
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2.6. Preparation of Purines by Ring-Closing of Pyrimidines and 
Imidazoles 
Sometimes it is desirable to functionalise either a pyrimidine or imidazole compound first 
then ring-close the other ring to construct the purine ring system. This can be necessary when 
it is difficult to obtain good yields or regioselectivity from functionalization of an intact 
purine ring system.  
For example, 4-chloro-5-aminopyrimidines (25c) can be aminated with a primary amine via 
an SNAr-type reaction to give substituted 4,5-diaminopyrimidines which can then be reacted 
with carboxylic acids or similar derivatives to give 8-substituted purines (33) (Scheme 
12).
28,52
  
 
Scheme 12. Mechanism of amination and ring-closing to obtain purine ring system (33) using 
carboxylic acid derivatives. R’’=H, alkyl, etc. 
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Alternatively, 4-amino-5-cyano-1-substituted-imidazoles may be treated with formamidine 
acetate to give 9-substituted-adenines (Scheme 13).
53
  
 
Scheme 13. Reaction of 4-amino-5-cyanoimidazole (26b) with formamidine acetate to give  
9-substituted adenines (7). 
It should also be mentioned that an oxo- functional group can be obtained by ring-closing  
4,5-diaminopyrimidines with carbonyldiimidazole (Scheme 14). 
 
Scheme 14. Mechanism for the reaction of 4,5-diamino-pyrimidines (25e) with carbonyldiimidazole 
to give 8-oxopurine compounds (34). 
2.7. Hydrolysis of Halogenated Purines 
8-Halopurines may be converted to 8-oxopurines by acid- or base-catalysed hydrolysis.
54
 In 
the case of acid-catalysed hydrolysis (Scheme 15), a proton adds to the N-7 of the purine and 
the double-bond electrons transfer to the nitrogen, creating a positive charge on C-8. A water 
molecule can then attack the nucleophilic C-8 to create a tetrahedral intermediate, which can 
then eliminate a water molecule to obtain the 8-oxopurine derivatives (3). 
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Scheme 15. Assumed mechanism of acid-catalysed hydrolysis of 9-substituted-8-haloadenines (6 or 8) 
to give 9-substituted-8-oxoadenines (3). 
In the base-catalysed reaction (Scheme 16), the base extracts a proton from a water molecule, 
giving an activated hydroxy group, which can then attack the C-8 of the halopurines and 
result in an SNAr reaction to give compounds (3).
28
 
 
Scheme 16. Assumed mechanism of base-catalysed hydrolysis of 9-substituted-8-haloadenines  
(6 or 8) to give 9-substituted-8-oxoadenines (3). 
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CHAPTER 3 
3. SYNTHESIS OF TARGET MOLECULES 
3.1. General 
The synthesis of the target molecules presented some challenges and, despite the structural 
similarity of these compounds, a variety of synthetic methods were used to obtain the final 
compounds. Compounds 3a, 3b and 3d have been synthesised earlier by a different route and 
for other purposes and this method is shown below (Scheme 17).
55
 That route involved the 
creation of a 1-substituted imidazole ring (26c) using triphosgene (35), the relevant primary 
amine and aminomalononitrile.
55,56
 The pyrimidine ring was then closed using formamidine 
hydrochloride to give 3. The yields for these steps are presented in Table 1. 
 
Scheme 17. Previously published method of synthesising 9-substituted 8-oxoadenines (3). 
Table 1. Summary of relevant results from the known synthesis route.
55,56
 
Entry R Imidazole step 
[%] 
Pyrimidine step 
[%] 
Overall yield  
[%] 
1 a: Benzyl 85 80 68 
2 b: Cyclopentyl   No information given 
3 d: Phenyl 73 74 53 
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This reaction is elegant on paper, but it should be noted that although triphosgene is claimed 
to be safer than phosgene and diphosgene, its vapour phase is still reported to be toxic. In 
addition, the first two steps of this reaction to create the imidazole ring involve the evolution 
of two equivalents of phosgene gas to each mole of product created. Without having first-
hand experience of this reagent, it seemed to have valid safety concerns. 
With this in mind, a new strategy for obtaining the target molecules was designed. By 
considering the structure of the target molecules, it could be seen that, starting from purine, 
there are three functional groups that are attached to the main bicyclic structure. The amine 
group on C-6 could easily be obtained by using commercially-available adenine as a starting 
point. The oxo group on C-8 could be established in two steps through halogenation and 
subsequent hydrolysis. The R group on N-9 could be attached through N-alkylation or N-
arylation.  
There are therefore three transformations that must be carried out starting from adenine to 
synthesise the target molecules and three synthetic pathways can be imagined to accomplish 
these transformations (Scheme 18). In the interests of reaction economy, it would be logical to 
introduce the different side-groups as late as possible (Route compounds 4 to 5 to 2 to 3). 
However, alkylation of compound 2 appeared more complicated than alkylation of 
compounds 5 based on similar reported reactions,
57
 with not only the question of 
regioselectivity, but also dialkylation. It was thus seen to be best to attempt first alkylation of 
5 – which should only give monoalkylated products,28 then hydrolyse to 3.  
 
Scheme 18. The initial possible routes for synthesising the target molecules (3). 
28 
 
3.2. Strategy 1 – Bromination, Alkylation and Hydrolysis 
The synthetic route for the target compounds, 9-substituted 8-oxo-9H-purin-6-amines (3), is 
outlined in Scheme 19. The initial approach to obtain the target molecules was to brominate 
adenine (4) at the C-8 position and then alkylate the resulting compound 5 with the relevant 
alkylating at N-9. The result was expected to be a mixture of 9- and 3-regioisomers. This 
mixture of isomers would then be separated by flash chromatography and the desired N-9 
isomer (6) was to undergo hydrolysis to obtain the target molecules (3). 
 
Scheme 19. Route for bromination, benzylation and hydrolysis. 
3.2.1. Bromination of Adenine  
Bromination of adenine was achieved through a literature procedure by treating adenine (4) 
with liquid bromine at ambient temperature for 5 h (Scheme 20).
58,59
 After neutralisation, 
washing and drying, the result was the desired product (5) as a beige powder in a good 74% 
yield. 
 
Scheme 20. Bromination of adenine (4) using liquid bromine. 
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3.2.2. Alkylation of 8-Bromoadenine with Benzyl Bromide 
9-Alkylation of 8-bromoadenine (5) with benzyl bromide to prepare compound 6a was 
attempted by generally following the procedure used for 9-alkylation of 8-bromoadenine with 
4-bromobutyl acetate in the presence of potassium carbonate, which involved heating the 
reaction mixture at 135 °C for 8 h, which is reported to give 45% 9-substituted and 22% 3-
substituted product.
58
 Benzylation using benzyl chloride instead of benzyl bromide has been 
reported, but the yields are lower (32% and 15% for 9- and 3-substituted, respectively).
60
 
Based on the reported yields, the first method was pursued for the current project (see  
Scheme 21). 
 
Scheme 21. General scheme for alkylation of 8-bromoadenine (5) under basic conditions. 
It was decided to try this reaction at the 135 °C overnight. Unfortunately, these conditions 
resulted in many products that were inseparable via flash chromatography (Table 2, Entry 1). 
The procedure was also carried out at a lower reaction temperature (ambient temperature), 
unfortunately giving similar results (Entry 2). By repeating the first reaction and tracking the 
reaction progress via TLC, it was observed that multiple spots started appearing after 4 hours 
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(Entry 3). The most successful results obtained in the current project were accomplished by 
both shortening the reaction time and using ambient temperature. Conducted at ambient 
temperature for 4 h (Entry 4), the reaction gave two monoalkylated products (6a and a 
monoalkylated by-product, 30a or 36a, see Scheme 21) and a small amount of dialkylated 
product (not isolated pure), all running close on silica TLC in various eluents.  
 
Table 2. Summary of results from 
1
H NMR spectra of the crude reaction mixtures from experiments 
during optimisation of the synthesis shown in Scheme 21.  
Entry 5 
[mmol] 
K2CO3 
[eq] 
T  
[°C] 
t  
[h] 
DMF  
[mL] 
Crude NMR 
1 1 2 135 16 5 Multiple purine and 
benzyl CH2 peaks 
2 1 2 r.t. 16 5 Multiple purine and 
benzyl CH2 peaks 
3 1 2 135 4 5 Fewer purine and benzyl 
CH2 peaks than for 
Entries 3 and 6 
4 1 2 r.t. 4 5 1:2 6a:30a/36a 
5 0.5 2 40 4 5 1:2 6a:30a/36a and 
additional purine and 
benzylic methylene peaks 
6 0.5 2 0 4 5 1:9 6a:30a/36a 
 
To see if further change in temperature could improve regioselectivity, small-scale reactions 
were carried out at 40 °C and 0 °C (Entries 5 and 6, respectively). The first increased the 
number of products produced in the reaction while lowering the temperature to 0 °C appeared 
to favour the undesired by-product. These conclusions are drawn from a combination of TLC 
and inspection of the 
1
H NMR spectrum of the crude mixture for these reactions, by 
comparing the integral values of the benzylic methylene signals. The shifts for these signals 
had been obtained in previous attempts and have also been reported in literature.
60
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9-Benzyl-8-bromo-9H-purin-6-amine (6a) was finally obtained by treating 8-bromoadenine 
(5) with benzyl bromide in the presence of a potassium carbonate for 4 h (Scheme 21). 
Unfortunately, this method gave a low yield of 15% for the desired product and a much higher 
yield of 42% for the by-product (30a or 36a).   
Based on reported alkylations and arylations of 8-bromoadenine, the main product was 
expected to be the 3-alkylated regioisomer since alkylation of 8-bromoadenine under basic 
conditions is reported to often give mixtures of the 3- and 9-alkylated isomers.
42,57-61
  
However, when it came to characterisation of this compound, the position of the benzyl group 
was unable to be ascertained with certainty by NMR techniques and could be either the  
1-benzylated (36a) or 3-benzylated (30a) isomer (see Scheme 21). Furthermore, the 
1
H NMR 
spectrum of the same compound showed some intriguing features discussed below, and hence 
NMR and X-ray structural studies were carried out on this compound.  
3.2.2.1. NMR Spectroscopy Investigations 
The spectral data for the major product (30a or 36a) were in good agreement with what has 
been reported for compound 30a before, but in the literature, structure elucidation is claimed 
to be based on 
1
H-
13
C HMQC and HMBC NMR (no details given).
60
 However, despite both 
the proton and carbon spectra for our product being in good agreement with the literature 
data, the HMBC data we obtained were inconclusive.  
The CH2 protons correlate to two carbon shifts; the C-2 at 143.9 ppm and a peak at 149.8 ppm 
(quaternary C). It was not possible to determine of the latter peak was the C-4 or C-6 shift and 
hence it was not possible to determine if the benzyl group was situated at N-3 or N-1. Both the 
peak at 149.9 and a second peak (quaternary C) at 153.6 ppm correlated to H-2 and neither 
correlated with the NH2 in the HMBC spectrum (see Spectrum 1 and Figure 14 below). 
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Spectrum 1. HMBC spectrum of the major isomer formed from the reaction shown in Scheme 21 
with the problem indicated. 
 
Figure 14. The possible structures of the two isomers that are in agreement with the relevant and 
possible HMBC correlations. 
 
C-4 and C-6 
C-5 
Ar-CH 
Ar-C 
C-8 
C-2 
CH2 H-2 
CH2 to C-4 
or C-6? 
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Several reports have been published on the formation of N-3 alkylated 8-bromoadenine, 
where the structure elucidation is reported to be based on 
1
H-
13
C HMQC and HMBC 
NMR.
42,59,60
 As our NMR studies were inconclusive, we decided to determine with absolute 
certainty whether the major product formed was the isomer 30a or 36a. For these purposes, 
we turned to X-ray crystallography.  
3.2.2.2. X-ray Crystallography Investigations 
Prior to this investigation, crystal structures of ten 8-bromoadenines were available in the 
Cambridge Structural Database (CSD, Version 5.31 of November 2009).
62
 However, all these 
molecules are 9-substituted. No 1- or 3- substituted 8-bromoadenines are previously reported 
in the database. 
The result of the X-ray structural investigation shown in Figure 15, confirms that isomer 30a 
has been crystallised. This is not only the first ever X-ray structure of an N-3 functionalised  
8-bromoadenine, but in fact also the first X-ray structure of an N-3 functionalised adenine 
where neither N-7 nor N-9 act as ligands for metal ions or carry additional functional groups.  
The asymmetric unit consists of two rotamers of compound 30a. Both forms correspond to the 
amino tautomer and both amino H-atoms were easily located in the electron density map and 
participate in strong hydrogen bonds as shown in Figure 16. Bond lengths and bond angles are 
roughly the same for the two forms. 
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Figure 15. The two adenine molecules in the asymmetric unit of compound 30a with atomic 
numbering indicated (not in correct crystallographic positions relative to each other). Displacement 
ellipsoids are drawn at the 50% probability level; H atoms are spheres of arbitrary size. Important 
bond lengths (in Å) have been indicated, estimated standard deviations are 0.005 - 0.006 Å. The 
different orientations of the benzyl groups are defined by the torsion angles C2A-N3A-C10A-C11A = 
70.6(6)°, N3A-C10A-C11A-C12A = 76.7(6)°, C2B-N3B-C10B-C11B = 90.8(6)° and N3B-C10B-
C11B-C12B = 177.7(5)°. 
 
Figure 16. Adenine molecules of compound 30a connected by hydrogen bonds into one-dimensional 
chains or tapes. The indicated H···N distances are in the range 2.09(4) - 2.16(3) Å. It can be seen that 
molecule A participates in a larger number of strong interactions as the aromatic N atoms accept a 
total of three H atoms compared to only one H atom for molecule B. 
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3.2.2.3. Tautomeric Considerations 
In the 
1
H NMR spectrum of compound 30a in DMSO-d6 solution, there are two distinct NH 
signals (8.07 and 8.23 ppm), in contrast to the spectrum of the 9-benzylated product 6a where 
one broad singlet for the NH2-group is observed (see Spectrum 2 below). Two NH signals have 
also been observed in spectra of other 3-alkylated adenines,
57,59-61
 but this phenomenon is 
only discussed in one publication and the hypothesis presented is that the compound studied 
must exist in solution as an imine tautomer, but no experimental evidence is given.
61
  
 
Spectrum 2. 
1
H spectra of 3-benzyl-8-bromoadenine (30a). 
It was hypothesised that the reason for the splitting of the NH signals could either be that 
compound 30a exists in solution as an imine tautomer 37a or 37b (Figure 17) or that there is a 
restricted rotation around the N
6
-C-6 bond leading to two resonances for the NHa and NHb as 
they are chemically different as seen for resonance forms 37c or 37d (Figure 18). The fact that 
calculations indicate that the amino tautomer of 3-methyladenine is more stable than any of 
the possible imine forms in the gas phase,
63
 supports the latter hypothesis shown in Figure 18. 
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Figure 17. Possible tautomers 37a and 37b of compound 30a in solution. 
 
Figure 18. Three resonance forms 37c and 37d that may contribute to the structure of 30a. 
1
H-
15
N HSQC NMR spectroscopy showed that both NH signals correlated to the same 
nitrogen signal at 125.7 ppm (relative to 
15
NH3), proving that compound 30a exists as the 
amino tautomer in solution (DMSO-d6), with 37c and/or 37d contributing to the difference in 
chemical environment of the two NH protons.  
It is interesting to note that the NH2 in compound 30a is shifted substantially downfield 
compared to for instance the NH2 in 9-methyladenine which resonances at 79.6 ppm  
(-300.9 ppm relative to Me
15
NO2)
64
 indicating more sp
2
 character for the N
6
 in compound 
30a. This supports the explanation for the splitting of the NH signals based on hindered 
rotation of the C-N bond. The coalescence temperature for the NHa and NHb protons was not 
determined, but at 65 
o
C only one broad signal from the NH2 could be seen in the 
1
H NMR 
spectrum.  
37 
 
3.2.2.4. Conclusions of this Study 
In summary, we have shown with absolute certainty that benzylation of 8-bromoadenine in 
the presence of K2CO3 gives a mixture of the N-3 and the N-9 alkylated isomers, with the 
former as the major product. The N-3 selectivity is higher when the reaction is conducted at 
ambient temperature compared to elevated temperatures. Furthermore, it is shown that the  
3-benzyl adenine derivative exists as the amine tautomer in both the crystalline state as well 
as in solution (DMSO-d6), but with restricted rotation around the N
6
-C-6 bond. The results of 
this study have been submitted and accepted for publication in the Journal of Heterocyclic 
Chemistry (see Author Proof in Appendix 1).
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3.2.3. Alkylation of 8-Bromoadenine with (Cyclohexyl)methyl Bromide 
Despite the results from benzylation of 8-bromoadenine, the same procedure was attempted  
to synthesise 9-(cyclohexylmethyl)-8-oxo-9H-purin-6-amine (6c). The alkylation step  
(Scheme 22) proved equally, if not more challenging than the benzylation of the same 
substrate. The experiment was followed on TLC over 4.5 h in the first attempt and run over  
1 day in the second attempt. 
 
Scheme 22. Alkylation of 8-bromoadenine (5) with (cyclohexyl)methyl bromide. 
Examination of the 
1
H NMR spectra of the crude mixtures of these experiments showed that 
the overall conversion from starting material to two mono-alkylated products was nearly 
identical (37% and 38%, respectively) and the ratio of 9-alkylated to another mono-alkylated 
product was similar (4:3 and 1:1, respectively) (Table 2). The 9-alkylated product (6c) and by-
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product (not isolated in pure form) ran very close on TLC using various eluents and 
separation by column chromatography gave only 14% of the desired product pure and impure 
fractions of the by-product. The structure of the 3-alkylated product was postulated by 
comparison of the 
1
H NMR spectrum and retention factor values with those from the 
benzylation reaction). The results of this alkylation were not satisfactory and the amount of 9-
alkylated isolated was too small to attempt the next step.  
Table 3. Calculated yield of starting material, 9-alkylated and 3-alkylated in crude product, 
determined from 
1
H NMR spectra of the crude mixtures, from the reaction shown in Scheme 22. 
Entry t  
[h] 
Unreacted starting 
Material [%] 
N-9 alkylated 
[%]  
N-3 alkylated 
[%] 
1 4.5 63 21 16 
2 24 61 19 19 
3.2.4. Hydrolysis of Monoalkylated-8-Bromoadenines 
There are several known methods for carrying out hydrolysis of a bromo group to an oxo 
group in an adenine compound. One way is to treat the 8-bromoadenine derivatives with 
sodium acetate in acetic acid under reflux for 8 h.
57
 An alternative method is by heating the 
substrate at reflux in 1M aqueous sodium hydroxide for 90 min.
66
 The chosen method was a 
third alternative, using formic acid at high temperature to obtain the hydrolysed product.
54
 
Compound 6a was thus hydrolysed to the desired target molecule, 6-amino-9-benzyl-7H-
purin-8(9H)-one (3a), by heating at reflux in formic acid overnight and purified by flash 
chromatography, resulting in 85% yield (Scheme 23).  
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Scheme 23. Hydrolysis of 9-benzyl-8-bromoadenine (6a) with formic acid. 
The 3-benzylated isomer (30a) was also hydrolysed using the same reaction conditions to give 
33 % of to 6-amino-3-benzyl-3H-purin-8(7H)-one (38a) after recrystallization (Scheme 24).  
 
Scheme 24. Hydrolysis of 3-benzyl-8-bromoadenine (30a) with formic acid. 
The lower yield of 33% for the hydrolysis of compound 30a is possibly a reflection of the 
purification method used. At first, both the 9- and 3-oxoadenines (3a and 38a) were purified 
by recrystallization from chloroform/methanol with 37% and 33% yields, respectively. 
However, it was subsequently discovered that carrying out flash chromatography on the crude 
mixture from the former substrate gave a high yield of 85%. Hydrolysis of compound 30a 
was not repeated to test the effect on purification methods, because this compound was not a 
target molecule. 
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3.2.5. Conclusions 
The described strategy consists of three steps where the first and last (based on one substrate) 
allow good yields. The major disadvantage of the strategy is the second step of N-9 alkylation. 
The main problem for the second step was the low conversion to the desired product. In 
addition, the monoalkylated-8-bromoadenine compounds are very polar and this resulted in 
low solubility on the flash column. This factor, in combination of with similar Rf-values and 
the tailing effect brought on by the presence of the amino-group on C-6, resulted in very 
difficult separations during flash chromatography, with many mixed fractions and only a 
small percentage of the desired products isolated in pure form. The overall yield for the 
synthesis of compound 3a using Strategy 1 was 9%. 
It is interesting to note that the ratio of the isomeric products is different for the reaction with 
benzyl bromide and those with (cyclohexyl)methyl bromide. Possible factors may be sterical 
effects from the halide, electronic effects, and the identity of the alkylating agent or base, 
among other factors. It could be interesting to carry out a survey of the alkylating patterns of 
8-substituted adenines at some time. Further research toward this may provide useful 
information in functionalization of adenines. 
Because of the poor results in the second step of the synthetic pathway, it was seen as 
undesirable to pursue further optimisation or to attempt this strategy with other  
9-substituents. 
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3.3. Strategy 2 – Bromination, Hydrolysis and Alkylation 
3.3.1. General 
Since the initial approach (see Section 3.2) did not give as good results as had been hoped, it 
was decided to attempt a different approach to the synthesis to hopefully improve yields and 
separation. Carrying out the hydrolysis of the 8-bromo group before introduction of the side-
group on N-9 could result in easy access to a range of 9-substituted 8-oxoadenines (3) and 
reaction economy with fewer reactions to reach multiple analogues of compound 3  
(Scheme 25).  
 
Scheme 25. Alternative synthesis of target compounds 3 via bromination, hydrolysis and alkylation. 
3.3.2. Hydrolysis of 8-Bromoadenine 
Hydrolysis of 8-bromoadenine (5) has been reported twice in literature – one with the use of 
acetic acid and once with formic acid.
67,68
 We decided to use formic acid to keep the step the 
same as the hydrolysis step in Strategy 1, especially since literature reported similar yields of 
83% and 88%, respectively, for the two procedures. 
8-Bromoadenine (5), which had been synthesised as described in Section 3.1, was thus 
hydrolysed by heating 8-bromoadenine at reflux in formic acid overnight. Recrystallization 
from water gave the product in a 58% yield (Scheme 26). The NMR data was in good 
agreement with the literature.
57,67
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Scheme 26. Hydrolysis of 8-bromoadenine (5) to 8-oxoadenine (2a). 
3.3.3. Alkylation of 8-Oxoadenine 
Alkylation of 8-oxoadenine has been reported once previously.
57
 In that procedure,  
8-oxoadenine was treated with a sodium hydride and the alkylating agent added after 1 h at  
110 ºC. The mixtures were then stirred at the same temperature for a period varying between 
4 h and 25 h. The results were mixed with reported yields varying for each alkylating agent. 
Yields of the monoalkylated products ranged from 29% to 55% and yields of the dialkylated 
products ranged from 20% to 34%.
57
 
It is reported that ratio of the mono- and dialkylated products is affected by the excess of 
alkylating agent (more alkylating agent is observed to give more dialkylated product).
57
 The 
amount of alkylating agent was therefore kept low – 1.2 equivalents. Since we considered that 
a weaker base should be sufficient to deprotonate at least one proton on N-9 or N-7, it was 
decided to use potassium carbonate instead of sodium hydroxide. In addition, it was decided 
to begin at ambient temperature and increase the temperature if necessary. Compound 2 was 
then reacted with three alkylating agents – benzyl bromide, (cyclohexyl)methyl bromide and 
cyclopentyl bromide.  
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Scheme 27. Reaction of 8-oxoadenine (2a) with alkyl bromides under basic conditions. 
3.3.3.1. Alkylation of 8-Oxoadenine with Benzyl Bromide 
Alkylation of 8-oxoadenine (2a) with benzyl bromide was initially planned to be carried out 
under the same conditions as was previously done for the alkylation of 8-bromoadenine (5). 
However, the reaction time was reduced from 4 h to 3 h because additional by-products 
appeared to be forming as judged from TLC taken during the reaction period. This method 
gave 19% (36 mg) 9-benzyl-8-oxoadenine (3a) and the 7,9-dialkylated product (39a) (~30%, 
impure).  The separation of the products was significantly better than that presented in Section 
3.1 even though the conversion and yield was not improved.   
3.3.3.2. Alkylation of 8-Oxoadenine with (Cyclohexyl)methyl Bromide 
For reaction of compound 2a with (cyclohexyl)methyl bromide to give compound 3c, the 
conversion rate in the alkylation step proved much slower than in the case of benzylation of 
the same substrate. This was not unexpected since (cyclohexyl)methyl bromide was also 
observed to be slower to react in the alkylation of 8-bromoadenine.  
This difference could be explained by benzyl bromide being able to form a resonance-
stabilised cation and undergo a more SN1-type substitution whereas the cation intermediate of 
(cyclohexyl)methyl bromide would only be stabilised by inductive donation from the 
cyclohexyl group.
31
 Of course, both substrates could undergo SN2 substitution since they are 
primary alkyl halides,
31
 so the difference may be that benzyl bromide reacts via a different 
mechanism.  
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As a result, the reaction mixture had to be warmed, in the first instance to 50 °C, then 70 °C in 
the second. In addition, the reaction time was increased to 21 h and 24 h, respectively. At  
50 °C, the conversion was approximately 30% from crude NMR and appeared greater at  
70 °C on inspection via TLC. However, crude NMR indicated that several purine compounds 
were being produced. Similar yields of 28% and 21%, respectively, were obtained with more 
starting material being recovered from the first instance. TLC indicated more dialkylated 
products being formed at the higher temperature and after flash chromatography; several 
mixed fractions indicating multiple dialkylated products were isolated (see Table 4).  
Table 4. Results of alkylation of compound 2 with (cyclohexyl)methyl bromide. 
Entry T  
[°C] 
t  
[h] 
Yield of N-9 alkylated 
(3c) [%] 
Yield of 7,9-dialkylated 
(39c) [%] 
1 50 21 21 Not isolated 
2 70 24 28 ~3 
 
The structure of the dialkylated compound isolated in the most pure fractions were indicated 
by 2D NMR to be the dialkylated structures shown in Scheme 27 – i.e. 7,9-dialkylated, as was 
also seen for the benzylation attempt. 
3.3.3.3. Alkylation of 8-Oxoadenine with Cyclopentyl Bromide 
Alkylation of 8-oxoadenine (2a) with cyclopentyl bromide was also carried out, at slightly 
lower temperature (40 ºC) and over a longer period of time than the initial conditions used for 
alkylation with (cyclohexyl)methyl- bromide to try to avoid the multiple dialkylated by-
products seen in those alkylations. However, since cyclopentyl bromide is a secondary alkyl 
halide, it is more sterically hindered than either of the other alkylating agents and thus less 
accessible for nucleophilic attack.
31
 After 2 days, there was observed only ~15% conversion 
by inspection of the 
1
H NMR spectra of the crude mixtures. The temperature was raised 
slightly to 60 ºC and the conversion did not increase significantly, although TLC indicated 
more by-product formation.  
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When the reaction was stopped and worked up after 3 days at the higher temperature, there 
were three intense spots and several less intense spots visible on TLC. Crude NMR was not 
easy to interpret with several overlapping signals. The ratio of starting material to the two 
major products was estimated to be approximately (2:1.3:1 2a:3b:39b). After flash 
chromatography, the desired N-9-product was isolated in 20% yield and impure by-product 
(12%) also isolated. 
3.3.4. Summary of the Alkylation of 8-Oxoadenine 
The results of the alkylation of 8-oxoadenine (2a) are summarised in Table 5 below. The 9-
monoalkylated compounds (3) were isolated in 15%, 28% and 27% yields, respectively. 
Impure 7,9-dialkylated products were also isolated in approximately 30%, 3% and 12% yields 
in addition to the observation of various other by-products in all three cases.  
The impurities in the reactions with benzyl bromide and cyclopentyl bromide are assumed to 
be another dialkylated purine (possibly N
6
, N-9), whereas DMF is the impurity in the reaction 
with (cyclohexyl)methyl bromide. The literature procedure mentioned in Section 3.3.3 
involved the use of preparative chromatography on silica gel plates followed by 
recrystallization. That method may have given pure dialkylated product but on the scale 
carried out in this project, this was not practical. If the results had been promising, up-scaling 
would have allowed further purification of the by-product. 
Table 5. Summary of the conditions and results obtained from alkylation of compound 2a as shown in 
Scheme 25, indicating the yield of products and recovered starting material (R.S.M.). 
Entry R t 
[ºC] 
T 
[h] 
Yield of 
monoalkylated 
[%]  
Yield of 
dialkylated 
[%] 
R.S.M. 
[%] 
1 a: Benzyl r.t. 3 19 ~30 (impure) - 
2 c: Cyclopentyl 40  
60 
48 
72 
27 ~12 (impure) 27 
3 b: (Cyclohexyl)methyl 50  21 28 ~3  
(impure) 
60 
46 
 
3.3.5. Conclusions 
Steps 1 and 2 of this synthesis route worked well with moderate yields. However, the third 
step gave poor results and it appeared that this method was also not the ideal method of 
producing N-9-alkylated products (3) in high yields. The conditions in the third step produced 
a variety of dialkylated products (39), which resulted in a less straightforward purification via 
flash chromatography than had been expected. In addition, it seemed that raising the 
temperature to increase the rate of conversion resulted in the production of more undesired 
dialkylated product. The overall yields were 6%, 12% and 12% for 3a, 3b and 3c, 
respectively. 
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3.4. Strategy 3 – Alkylation, Bromination, Hydrolysis 
3.4.1. General 
An alternative approach to the synthesis of the target molecules was to reverse the first two 
steps shown in Scheme 19 above and N-alkylate adenine (4) before bromination at C-8 (see 
Scheme 28). The resulting 9-substituted 8-bromoadenines (6) could then be hydrolysed in the 
manner shown in earlier in Scheme 23 to give the target compounds (3).  
 
Scheme 28. Third possible route for synthesis of 9-substituted-8-oxoadenines (3). 
3.4.2. Alkylation of Adenine 
N-Alkylation of adenine (4) was carried out through a literature procedure where adenine was 
reacted with an alkyl halide in dry DMF employing potassium carbonate as a base (Scheme 
29).
34
 Using benzyl bromide as the alkylating agent, the reaction time used was 4 h while for 
reactions using the less reactive (cyclohexyl)methyl bromide and cyclopentyl bromide a 
reaction time of 72 h was required for complete conversion (Table 6). 
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Scheme 29. Alkylation of adenine (4) using alkyl halides under basic conditions. 
According to literature, in some of these reactions the N-7 isomer has been found to be 
produced in addition to the N-9, although in much lower yields (9%-27%).
34
 However, 
examination of NMR data obtained in the course of this project was not in agreement with 
these claims. The major products obtained by us were indeed the 9-alkylated isomers (7), but 
the minor products were discovered through 2D NMR experiments to be the 3-alkylated (28) 
and not the 7-alkylated adenines (29). The results of the alkylation step are shown below in 
Table 6. A brief discussion of the characterisation of the by-product follows. 
Table 6. Results of alkylation of adenine (4) to give compounds 7a-c and 28a-c (isolated yields).  
  Entry R Yield of N-9 [%] Yield of N-3 [%] 
1 a: Benzyl 53 23 
2 b: Cyclopentyl 70 7 
  3 c: (Cyclohexyl)methyl 71 13 
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3.4.2.1. Characterization of the By-product 
In literature, the assignment of the minor product as the 7-alkylated isomer was achieved by 
selective irradiation of the hydrogens on the carbon closest to N-7. In this case, the benzyl-
methylene atom in both products was irradiated. For the N-9-benzylated adenine (7a), a NOE 
correlation to both the purine CH signals (H-2 and H-8) was seen. For the by-product 
(reported to be N-7 alkylated, 29a), only one correlation was visible (see Figure 19). 
According to the article, the by-product was thus confirmed through NOE difference 
spectroscopy to be 7-alkylated (29a).
34
 
 
Figure 19. Diagram indicating the expected NOE correlations for the N-9 (7a) and N-7 (29a) 
benzylated adenines. 
In an article published earlier by the same authors, this structure elucidation by NOE 
difference spectroscopy for the same compounds is explained in more detail.
35
 It is claimed 
that irradiation of the protons on the side chain of the by-product results in a correlation to one 
of the purine CHs and in addition, the exo-cyclic NH2 group attached to C-6.  
Interpretation of the 2D NMR data (HMBC and HSQC) data obtained in the course of the 
current project indicated a 3-subsituted isomer (see Spectrum 3), so it was thus decided to 
carry out 1D NOE experiments to see if the results obtained in literature could be reproduced. 
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Spectrum 3. HMBC spectrum and drawing of minor isomer indicating the relevant correlations. 
 The benzylated by-product was used as the test compound since the literature did not obtain 
any by-product when cyclopentyl bromide was used and did not synthesise the 
cyclohexylmethyl analogue. The methylene protons on the benzylic side chain were irradiated 
first, and then the closest phenylic protons were irradiated.  
There was no visible correlation between the amino group on C-6 and any of the protons in 
the benzylic side-chain that should be closest to the groups if the benzyl group was located on 
N-7. Irradiation of the protons in the amino group gave no visible correlations. In addition, 
when irradiating the phenylic protons, a correlation was seen to H-2 and a very weak 
correlation to H-8, which seems unlikely to indicate N-7 alkylation but does not rule it out as 
a possibility. 
Although the absence of NOE correlations is not proof of which regioisomer has been 
produced, the visible signals in the HMBC spectrum does indicate that, in our hands, 
alkylated of adenine results in the 3-alkylated isomer (28a) being obtained.  
 
C-4 
C-5 
Ar-CH 
Ar-C 
C-8 C-6 
CH2 
H-2 
H-8 
NH2 
C-2 
CH2 to C-2  
CH2 to C-4 
CH2 
H-2 to CH2 
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3.4.3. Arylation of Adenine 
Arylation of adenine was planned to establish a phenyl ring on the 9-position. Previously, it 
had been reported that copper-catalysed coupling of phenyl boronic acid to adenine was 
unsuccessful in dichloromethane due to insolubility problems.
45
 Subsequently, there have 
been several papers reporting the use of water/methanol and DMF as solvents with 
corresponding good to very good yields (85%
43,44
 and 69%
42
) and it was decided to follow 
these procedures. 
The first attempt at preparing 9-phenyl-9H-purin-6-amine (7d) involved the coupling of 
adenine (4) and phenyl boronic acid in the presence of a copper catalyst. Adenine (4) was first 
treated with phenylboronic acid in the presence of copper diacetate monohydrate and 
tetramethylethlyenediamine using a solvent system of water and methanol (Scheme 30). 
Unfortunately, this gave only low yields (13% after 45 mins, 20% after 22 h, literature yield = 
85%).
43,44
 
 
Scheme 30. Attempted arylation of adenine. 
The same arylation was attempted with phenanthroline as a ligand and DMF as a solvent 
(Scheme 31).
42
 This procedure required the use of copper(II) acetate but did not specify if it 
was anhydrous or monohydrate. Since Yue,
44
 had indicated that changing to copper(II) 
monohydrate gave better yields than using the anhydrous copper(II) acetate, this was 
attempted first. These conditions gave a 9-substitued (7d) pure in 21% yield (literature yield = 
69%) and mixtures of 9-, 7- and 3-substituted product, identified by comparison of the 
1
H 
NMR spectra with NMR data from literature (calculated overall yields = 23%, 19% and trace, 
respectively). Repeating the experiment with anhydrous copper(II) acetate gave 17% 9-
substituted (7d) and ~25% 7-substituted (29d) (slight impurities) adenine. 
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Scheme 31. Second attempted arylation of adenine (4). 
As these approaches of arylating adenine did not give good yields, another synthetic route was 
designed for this target molecule (3d) (see Strategy 4). 
3.4.4. Bromination of the C-8 Position 
Bromination of the 9-alkylated purines (7) was carried out by two methods depending on the 
substrate (Scheme 32). 
 
Scheme 32. Methods of brominating the 9-substituted adenines (7) that were used in this project. 
For 9-cyclopentyladenine (7b), a literature procedure which employed a mixture of liquid 
bromine and water was used. This gave a good yield of 67%.
69
 The same procedure was also 
used on 9-(cyclohexyl)methyladenine (7c) and resulted in a similar yield (66%). For  
9-benzyladenine, the reported procedures involve the use of N-bromosuccinimide, in 
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chloroform at reflux
70
 or DMF at ambient temperature.
34,71
 Both these approaches were 
attempted and the results are presented in the table below (Table 7). 
Table 7.  Results of bromination of 9-benzyladenine (7a) with N-bromosuccinimide. 
Entry NBS 
[eq] 
Solvent T  
[˚C] 
t (lit.) 
[h] 
t (exp.) 
[h] 
Yield (lit.) 
[%] 
Yield (exp.) 
[%] 
1 3  DMF r.t. 12  24 23 42 
2 5  CHCl3 reflux 3  8 41 16 
Entry 1 – reference 34. 
Entry 2 – reference 69. 
 
For both these reactions, TLC at the conclusion of the reaction time given in literature 
indicated incomplete conversion. Using DMF as the solvent (Entry 1), after 24 h, TLC still 
showed incomplete conversion but more conversion than at 12 hours. For the reaction with 
chloroform at reflux temperature (Entry 2), TLC indicated nearly full conversion after 8 h, 
although a second spot formed close to the baseline, so conversion may not have been to the 
desired product, but to a much more polar by-product that was not isolated.  
Purification for both reactions was carried out as described in literature for each synthesis. 
The work-up for the reaction in DMF was flash chromatography, whereas for that in 
chloroform, the crude reaction mixture was washed with sodium sulfite and sodium chloride 
solutions. The aqueous work-up may have partially been the cause of the low yields in the 
second reaction (16%), and may have been unnecessary considering that a flash was sufficient 
to isolate the product for the first reaction (42%). In addition, the scale of the reactions (0.65 
mmol – 0.86 mmol) may have been too small to be manageable and reflect losses during 
purification rather than indicating inefficiency in the reaction itself. It may be desirable to run 
the reaction using DMF as a solvent over a longer period of time if this was to be repeated. 
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3.4.5. Hydrolysis of 8-Bromoadenines 
The three 9-substituted-8-bromoadenines (6a, 6b and 6c) obtained were hydrolysed using the 
same method as described in Section 3.2.4 (Scheme 33). The benzyl and cyclopentyl 
substrates (3a and 3c) were hydrolysed overnight (20 h and 18 h, respectively). It should be 
mentioned that these reactions were not followed on TLC or NMR during the reaction period 
and these reaction times are therefore not optimised. However, based on TLC, the 
cyclohexylmethyl substrate (6c) seemed to require more time to obtain full conversion.  
 
Scheme 33. Hydrolysis of 9-substituted 8-bromoadenines using formic acid. 
TLC of the reaction mixture after 19 h indicated incomplete conversion. After 24 h, the 
conversion appeared to be greater. After 43 h, it appeared that the reaction had gone nearly to 
completion so it was worked up and purified. It is unknown what the cause of this much 
longer reaction time. 
The need for the longer reaction time (43 h) is under doubt as, later in the project, mixtures of 
8-bromo- and 8-chloroadenines (6 and 8) are hydrolysed with good yields (>90%) with a 
much short reaction time of only 18 h. This would indicate that hydrolysis of 8-
bromoadenines are possible with a shorter reaction time than used here. It would be desirable 
to repeat this reaction to confirm whether or not this long reaction time is needed, but this was 
not prioritised as sufficient amounts of the target compound (3c) had been obtained and due to 
time considerations of the project. The results of the three hydrolysis reactions are shown in 
Table 8. 
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Table 8. Results of hydrolysing 9-substituted-8-bromoadenines. 
Entry R t  
[h] 
Yield  
[%] 
1 a: Benzyl 20 85 
2 b: Cyclopentyl  43 78 
3 c: (Cyclohexyl)methyl 18 89 
3.4.6. Conclusions 
Strategy 3 was initially the least favoured of the three proposed routes in Section 1.3, since it 
had the worst reaction economy as the substitution on N-9 is carried out in the first step. 
However, the results obtained are the best out of the synthetic routes that had originally been 
envisioned, with overall yields of 19%, 37% and 42% for 3a, 3b and 3c, respectively. 
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3.5. Strategy 4 – Synthesis of 9-Phenyl-8-oxoadenine from 4,6-Dichloro-5-
aminopyrimidine 
3.5.1. General  
The second strategy for obtaining 9-phenyl-8-oxoadenine (3d) for biological testing was to 
aminate 4,6-dichloro-5-amino-pyrimidine (9) with aniline, then ring-close the substituted 
pyrimidine (10a) with carbonyldiimidazole. The final step would be to aminate at C-6 with 
liquid ammonia or ammonium hydroxide.  
 
Scheme 34. Alternative method of synthesis of 9-phenyl-8-oxoadenine (3d). 
3.5.2. Amination of 4,6-Chloro-5-aminopyrimidine 
The amination of compound 9 was carried out following the general scheme shown below 
(Scheme 35) with various reaction conditions (Table 9). 
 
Scheme 35. Amination of 4,6-dichloro-5-aminopyrimidine (9) with aniline. 
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Table 9. Different conditions used to aminate 4,6-dichloro-5-aminopyrimidine (9) (Scheme 35). 
Entry S.M.  
[mmol] 
Aniline  
[mmol] 
Reaction Conditions Yield of 
monoaminated 
(10a) 
[%] 
Yield of 
diaminated 
(10b) 
[%] 
1 2 2.6 6 mL water, 1 mL 
ethanol, 0.1 mL conc. 
HCl, reflux, 14 h 
69 - 
2 1.5  2 2.1 mmol 
triethylamine, 5 mL n-
BuOH (118 ˚C), 
reflux, 3 d 
68 - 
3 2 ~10 Aniline, 118 ˚C, 3 h - 15 and 55 
10b.HCl 
 
4,6-Dichloro-5-aminopyrimidine (9) was first aminated with aniline to give 6-chloro-N
4
-
phenylpyrimidine-4,5-diamine (10a) following a literature procedure (see Table 9, Entry 1).
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This reaction was also run in parallel with a longer reaction time (14 h) because TLC showed 
presence of starting material in the reaction mixture after the prescribed time (8 h). The longer 
reaction time had no affect on the conversion or yield.  
For comparison, the amination was also carried out using conditions that have been used 
earlier in the Gundersen group at UiO for amination of 9 with a primary amine. This 
procedure involved refluxing the starting material with the appropriate amine in the presence 
of triethylamine in n-butanol (Entry 2).
72
 Unfortunately, the method required a longer reaction 
time for complete conversion, had a more difficult separation at work-up, and gave no 
improved yield. In addition a disubstituted salt was observed in the crude reaction mixture 
(crude ratio: 77:23 10a:10b.HCl). This method was also carried out in parallel with double 
the amount of aniline to ascertain if the reaction time could be reduced, but this resulted only 
in a higher percentage conversion to the disubstituted salt (crude ratio: 23:77 10a:10b.HCl).  
The disubstituted compound and associated salt were identified from the third reaction of the 
pyrimidine with pure aniline (Table 9, Entry 3), where no monosubstituted product was 
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observed, but there was a quick conversion to the disubstituted product 10b. In this method, 
the starting material was simply heated in aniline at 118 ˚C (the boiling point of n-butanol). 
The method was carried out for comparison purposes with the other two methods, but also to 
obtain the expected diaminated compound that should be produced with a large excess of 
aniline for use in identification in the other reactions (Entry 3). 
 The compound 10b was obtained mostly as a hydrochloride salt that could be converted to 
10b by treatment with a base. In hindsight, it would have been logical to treat the crude 
mixture with a base before work-up to convert the hydrochloride salt to compound 10b. 
However, the information which was required from this experiment was obtained so no 
further work was carried out. 
There were reactions carried out using the Gundersen group’s conditions with different 
amounts of aniline (Table 10, Entries 1 and 2). These reactions were followed by examination 
of the crude by NMR spectroscopy after 1, 2 and 3 days and the results are presented in the 
table below (Table 10). The results indicate that complete conversion of the starting material 
requires three days, furthermore, allowing the reaction to run this long results in the 
production of a significant amount of dialkylated product. Based on ratios, using 1.2 eq of 
aniline and a reaction time of 3 days should result in the highest yield of compound 10a. 
However, if separation of 9 and 10a is simpler than that of 10a and 10b.HCl, using 2.5 eq of 
aniline and a shorter reaction time may be preferable. 
 
Table 10.  Ratios of the starting material to monoalkylated and dialkylated salt (9:10a:10b.HCl) in the 
reaction mixture after 1, 2 and 3 days and products from crude NMR spectroscopy. 
Entry Aniline 1 day [%] 2 days [%] 3 days [%] Yield (10a) [%] 
1 1.2 eq 60:40:0 41:59:0 0:77:23 68 
2 2.5 eq 38:62:0 0.1:44:56 0:23:77 ~16, impure 
 
For the amination step, it would seem that the first method was the most preferable method. 
However, it is curious to note that the reaction occurs much faster under acidic conditions 
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(Table 9, Entry 1) than basic conditions (Entry 2), with both methods giving similar yields. It 
should be noted that the first method (Entry 1) involved direct recrystallization of the crude 
mixture without the opportunity to examine the products at this stage by NMR spectroscopy. 
It is possible that the disubstituted product was produced in the reaction, but this was not 
ascertainable after following the given procedure and work-up. For all other reactions, flash 
chromatography was used for purification. 
One possible reason for the faster reaction rate under acidic conditions may be that the acid 
catalyses the reaction by protonating on one of the ring-nitrogens,
28
 thus reducing the 
electron-density in the ring further and increasing the attractiveness of C-4 and C-6 to 
nucleophilic attack. The ability of acid to accelerate nucleophilic attack on heterocyclic 
compounds has been discussed before in literature.
73,74
 This has perhaps a parallel in the acid-
catalysed hydrolysis of 8-halopurines to 8-oxopurines (see Section 2.6). 
The purpose of the base in the base-catalysed reaction seems to be to remove the excess 
hydrogen chloride which is the by-product of the aromatic substitution reaction. With a more 
reactive nucleophile such as a benzyl amine, the removal of the acid, which could catalyse the 
reaction, seems to affect the rate of the reaction less than with a less reactive nucleophile such 
as aniline. It is in any case not surprising that, under similar conditions, the reaction with 
aniline is slower than that with the benzyl amine when the difference in nucleophilicity 
between these types of amines is taken into consideration – i.e. benzyl amine being more 
nucleophilic than aniline.
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3.5.3. Cyclisation of a Diamino-pyrimidine with Carbonyl Diimidazole 
The cyclisation step was carried out on compound 10a with carbonyldiimidazole (CDI) 
(Scheme 36). This reaction had been reported to be employed on similar substrates (2-phenyl-
4,5-diaminopyrimidine and 4,5-diamino-6-chloropyrimidine) with good results (82% and 
86%, respectively).
76,77
 The first method had used THF as the solvent at ambient temperature 
for 2 h while the second employed 1,4-dioxane at reflux for 24 h.  
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Scheme 36. Cyclisation of compound 10a using carbonyldiimidazole. 
It was decided to use the less harsh conditions as a starting point, and after 6 h stirring in THF 
at ambient temperature, the reaction had gone to completion. Only the product and imidazole 
were observed in 
1
H NMR spectrum of the crude mixture. After flash chromatography, the 
product was obtained in good yields (97%).  
3.5.4. Amination of 6-Chloro-9-phenyl-7H-purin-8(9H)-one  
The final step of substituting the chlorine atom on C-6 with an amino group was more 
difficult than expected (Scheme 37). Direct substitution of the chloro-substituent with an 
amino group has not been successfully carried out previously on 8-oxoadenines. The closest 
related reactions are amination on halopurines with primary and secondary amines on  
8-oxo-halopurines.
78-80
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Scheme 37. Synthesis route of the target molecule (3d) from compound 11. 
Treatment of compound 11 with liquid ammonia at ambient temperature gave no reaction 
after 24 h. Due to restrictions on the sealed vessels available; this was not attempted at higher 
temperatures. Reaction with concentrated ammonia solution (28%) gave no reaction at 
ambient temperature. At 100 ˚C after 18 h, a small but visible amount of product was 
identified via inspecting the 
1
H NMR spectra of the crude mixture.   
The temperature was raised to 120 ˚C and the rate of the reaction increased slightly with 
approximately ~9% per day. When the temperature was raised to 150 ˚C, the reaction vessel 
did not tolerate these high pressures and the lid exploded after 2.5 h at this temperature. The 
amount of conversion after this time was estimated to be 10% over those 2.5 h from the 
1
H 
NMR spectrum of the residue in the reaction vessel. The reaction was attempted once more at 
130 ˚C and after being allowed to stir at that temperature for 7 days, the result was only 
slightly more than 50% conversion. 
Compound 11 proved surprisingly resistant to amination attempts. One explanation may be 
due the presence of the acidic proton on N-7 which would possibly deprotonate in a basic 
environment and make the purine ring less electrophilic – i.e. more electron-rich. The 
amination reaction installing only an amino group has in any case not previously or presently 
been reported on an 8-oxoadenine. 
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It was decided to treat 11 with a more nucleophilic primary amine and we chose to use a 
benzylamine and cleave off the attached benzyl group in the final step with acid.
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Benzylamines are more nucleophilic than ammonia
75
 and in particular para-
methoxybenzylamine, with its electron-donating methoxy group is even more nucleophilic 
and should have a greater rate of reaction in a nucleophilic attack than both unsubstituted 
benzylamine and ammonia.
82
   
The amination was thus carried out with para-methoxybenzylamine. The first experiment was 
carried out in ethanol at reflux. However the conversion was low (~50%) and the solvent was 
changed to n-butanol, providing a much higher reflux temperature and, as a result, full 
conversion. After partial purification, the product (12) was obtained ~90% pure and after 
cleavage of the benzyl group and purification via flash chromatography, this impurity was 
removed to give the target molecule (3d) pure (yield over two steps = 75%).  
A small amount of the impurity (20 mg) was isolated during flash chromatography in the final 
step and purified using recrystallization with chloroform and hexanes for structural 
determination. Structure elucidation with NMR spectroscopy and MS indicated that 
compound 12 had been isolated. However, when the amination step was repeated and the 
product recrystallized from the mixture, the two spectra were slightly different. The difference 
was mainly in the benzylmethylene protons. These appeared as a singlet in the impurity and a 
doublet in what was presumably compound 12. 
It is thus proposed that this impurity is in fact the hydrochloride salt of 12, which is logical 
since there was no base present in the reaction to consume the hydrogen chloride produced. 
Nether was neutralisation carried out during the work-up. If this was to be repeated, we would 
suggest the use of a base (perhaps triethylamine) that would both consume the hydrogen 
chloride in step 1. In fact, most of the previous work in this area (excluding where microwave 
irradiation has been used), has included some triethylamine in the reaction mixture. 
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3.5.5. Conclusions 
This synthetic strategy is clean, efficient and has given the target molecule (3d) in good yields 
(50% over 4 steps). It is undoubtedly an acceptable method to obtain 9-phenyl-8-oxoadenine. 
It would be interesting to carry out this synthesis route on the other target molecules to 
compare results.  
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3.6. Strategy 5 – Alternative Synthesis of 9-Phenyl-8-oxoadenine  
3.6.1. General  
Even though sufficient amounts of the target compound (3d) had been obtained via Strategy 4 
(see Section 3.5), it was desirable to establish if a synthetic route more similar to that used 
successfully for benzyl, cyclopentyl and cyclohexylmethyl analogues could be followed to 
obtain compound 3d – i.e. 9-substitution, halogenation then hydrolysis.  In addition, the route 
envisioned would allow for work in the area of the lithiation project already in progress in the 
Gundersen group at UiO. 
The synthetic route presented here (Scheme 38) was designed with the intention of acquiring 
a route that mirrored the most successful route used for the other target molecules – alkylation 
of adenine, followed by halogenation and hydrolysis. As indicated earlier in Section 3.4.3, 
attempts to carry out direct arylation of adenine were met with limited success. It was decided 
to begin with 6-chloropurine (13) and arylate according to a procedure used previously in the 
Gundersen group at UiO.
45
 This would be followed by amination, halogenation and 
hydrolysis (Scheme 38). 
 
Scheme 38. Third proposed synthesis for 9-phenyl-8-oxoadenine (3d). 
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3.6.2. Arylation of 6-Chloropurine 
The arylation of 6-chloropurine (13) was carried out under similar conditions to the reactions 
shown in Section 3.4.3, but using anhydrous copper(II) acetate instead of the monohydrate 
(Scheme 39), resulting in 72% yield of 6-chloro-9-phenylpurine (14). 
 
Scheme 39. Copper-catalysed coupling of 6-chloropurine (13) and phenylboronic acid. 
The comparably good yields obtained here may indicate that the results of the copper-
catalysed coupling may depend on the substrate used. It has been reported that copper(II) can 
form different complexes with adenine (4) and other purine-derivatives.
83
 Thus, in the case of 
arylation of adenine (4), it may be that either the product (7d) or the starting material (4), or 
both, are forming complexes with the copper that are not able to be isolated using the types of 
purification employed – flash chromatography, with or without  aqueous work-up.  
The arylation of 6-chloropurine (13) showed better regioselectivity than the arylation of 
adenine (4) under similar conditions. Only the 9-substituted product (14) was produced with 
6-chloropurine while the 9-, 7- and 3- substituted products (7d, 29d and 28d) were all 
observed from arylation of adenine. The ability of purines to form complexes with copper 
may also affect the regioselectivity of the reactions. For example, under the conditions used, 
copper could prefer to form a complex at N-3 and N-9 with 6-chloropurine (13) but with N
6 
and N-7 with adenine (4). In any case, it was clear that the method giving the highest yields of 
9-arylated purine in our hands was to arylate 6-chloropurine (13). 
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3.6.3. Amination of 6-Chloro-9-Phenylpurine 
The amination of compound 14 was carried out under the same conditions as those that were 
employed on the 8-oxo-analogue (11) (Scheme 40). Compound 14 was heated in concentrated 
ammonium hydroxide at high temperature in a sealed vial overnight. This gave an excellent 
yield of 95%. The combined yield for these two steps (68%) was thus much higher and 
comfortable to work with than the 20% obtained in the course of Strategy 3 (Section 3.4.3).  
 
Scheme 40. SNAr of chlorine in compound 14 with an amino group. 
3.6.4. Halogenation of 9-Phenyladenine 
The method of halogenation chosen was deprotonation of 9-phenyladenine (7d) using lithium 
diisopropylamide (LDA) generated in situ, followed by capture of the adenine anion with an 
appropriate source of electrophilic halogen (Scheme 41). There are no reported methods for 
carrying out this transformation and use of the lithiation/halogenation method added to an 
ongoing project in the Gundersen group at UiO which has the goal of screening substrates to 
ascertain which are amenable to undergoing halogenation at the C-8 position via this method 
(see Chapter 4).  
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Scheme 41. Lithiation of 7d and capture with hexachloroethane. 
For reasons that will be discussed in Chapter 4 (dedicated to the lithiation/halogenation 
research that was undertaken as part of a larger group project), the chosen electrophilic source 
was hexachloroethane. The reaction gave a yield of 67% of the desired product (8d) after 
aqueous work-up and flash. This result was as good as the highest yields seen when we 
brominated with bromine and water. Still, it would have been interesting to carry out a 
bromination using liquid bromine and water on this substrate (7d) in order to compare the 
results. 
3.6.5. Hydrolysis of 8-Chloro-9-phenyladenine 
Compound 8d was hydrolysed to the target molecule 3d using formic acid as described earlier 
in Section 3.2.4, giving a 73% yield (Scheme 42). 
 
Scheme 42. Hydrolysis of 8-chloro-9-phenyladenine (8d) to the target molecule (3d). 
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3.6.6. Conclusions 
This synthetic route gave an overall yield of 33% over 4 steps. The number of steps is the 
greatest difference compared to the similar routes where adenine is alkylated directly. On the 
other hand, this route (like that being with 4,6-dichloro-5-aminopyrimine in Strategy 4) has 
the advantage of being regioselective in the first step where the side-group is established. 
None of the other alkylation or arylation experiments carried out in the course of the current 
project are close to being regioselective – all resulted in reaction mixtures with more 
demanding purification. It is clear from both Strategy 4 and Strategy 5 that the exploitation of 
regioselective reactions is desirable to allow for more straightforward purification and 
conservation of time and resources. 
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CHAPTER 4 
4. LITHIATION AND HALOGENATION EXPERIMENTS 
4.1. Background to the “Lithiation Project” 
There are several reasons why a method for fast and efficient halogenation on a variety of 
substituted purine compounds is interesting. As mentioned earlier, 2-, 6- and 8-halopurines 
are important intermediates for the functionalization of purines, which are interesting and 
potential biologically-active compounds. There is thus a need to survey the flexibility of our 
method for halogenating the C-8 position of substituted purines, with the intention of creating 
more functionalisable molecules.
51
  
The “lithiation project” is an ongoing project in the Gundersen group at UiO that has been 
worked on by several other post-graduate students.
84,85
 This ongoing project has focused on 
the possibilities of efficiently generating 8-halopurines by lithiation (using LDA) and 
subsequent capture with a halogen electrophile (e.g. hexachloroethane, tosylchloride, 
dibromotetrachloroethane, and cyanogen bromide or cyanogen iodide).  
Several types of compounds with a variety of substitution patterns have already been surveyed 
using this method. Most of the recent work done on this project has been carried out on 6-
chloro-9-benzylated compounds.
49,85
 In the past year, studies have been conducted on a range 
of 6-chloro- and 6-amino-9-alkylated purines (Scheme 43).
84
  
 
Scheme 43. Work performed previously on this project.
49,84
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The experiments described in this chapter provide an alternative method of introducing a 
halogen on the C-8 of a 9-substituted adenine that can later be hydrolysed to the target 
molecules, and as such can be considered a direct parallel to the bromination experiments 
carried out in Section 3.4.4. The results will also add to the library of results obtained so far 
by the other members of the Gundersen group at UiO.  
4.2. Substrates used in this Study 
The substrates used in this part of the study are shown in Figure 20 below. A variety of 
aromatic and cyclic ring systems are represented. Most are adenine-derivatives and one is a 6-
chloropurine derivative. All the compounds are intermediates in strategies to obtain the target 
molecules and have all been synthesised from adenine (4) or 6-chloropurine (13) as described 
in Chapter 3. 
 
Figure 20. Substrates upon which lithiation / halogenation was attempted. 
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4.3. General Procedure 
The common method used for the lithiation and halogenation of 6,9-substituted purines is 
shown below (Scheme 44).  
 
Scheme 44. The common method for halogenation of the relevant purines is shown above. 
4.4. Halogenation of Adenine Substrates  
4.4.1. Capture with 1,1,2,2-Tetrachloro-1,2-dibromoethane 
Lithiation and capture with tetrachlorodibromoethane was carried out on compounds 7b and 
7c using 5 eq of LDA and 3 eq of the brominating agent. This gave a product which appeared 
nearly pure and was in agreement with the data obtained earlier. However, a small impurity 
was visible on the 
1
H NMR spectra at 8.12 ppm and 8.14 ppm for compounds 7b and 7c, 
respectively (Spectrum 4). This peak was in the typical purine region, but there did not appear 
to be any other unexpected peaks visible in the spectra.  
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Spectrum 4. 1H spectra of the isolated product from the lithiation and bromination of compound 7b. 
The impurity was not removed or reduced by flash chromatography or recrystallization in 
several combinations of solvents. The fact that it had very similar properties to the expected 
product led to the hypothesis that the impurity was actually another purine compound with 
slightly different substituents. 
From the carbon NMR spectrum of the product mixture (Spectrum 5), it became apparent that 
the impurity had a full set of purine signals which mirrored the shifts observed for the 
brominated compound, with the exception of C-8 (circled in Spectrum 5). It was then 
hypothesised that it was the identity of the substituent on the C-8 that was different in the by-
product. In addition, the substituent would have to be more strongly electron-withdrawing, 
thereby deshielding its neighbouring carbon more than bromine. 
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Spectrum 5. Purine region of the 
13
C spectra of the isolated product from the lithiation and 
bromination of compound 7b. 
The logical conclusion was that a small percentage of the starting materials were being 
chlorinated instead of brominated, resulting in the corresponding 9-substituted 8-
chloroadenines (8b and 8c). The identity of the by-product was confirmed by both ESI-MS 
and subsequently, the synthesis of the 8-chloroadenine analogues and comparison of their 
NMR data. 
The undesired chlorination has not been observed previously in this project, although another 
Masters student in the Gundersen group at UiO subsequently discovered a similar problem as 
a side-product to bromination of purine-derivatives using this method.
84
  
The suggested mechanism for capture of the anion intermediate with an electrophilic halogen 
(Scheme 45) has been shown in Section 2.3.3 (see Scheme 11).
85
 Bromination should be the 
dominant transformation, as the chlorine atoms should have greater electron-drawing strength, 
making the bromine atoms more electrophilic than any of the chlorine atoms. This hypothesis 
is consistent with the observation that the major product is the brominated product.  
C-6 (Br) 
C-6 (unknown) 
C-2 (Br) 
C-2 (unknown) 
C-4 (Br) 
C-4 (unknown) 
C-8 (Br) 
C-5 (Br) 
C-5 (unknown) 
C-4 (unknown) 
C-8 (unknown) 
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There are two theories proposed as to why this occurred and these are set out in Scheme 45 
and Scheme 46.  
 
Scheme 45. The proposed synthetic route used to create the mixtures of brominated (6) and 
chlorinated (8) products. 
 
Scheme 46. Possible nucleophilic aromatic substitution of 8-bromo-9-substituted adenines (6) by free 
chlorine anions. 
In the first proposed mechanism (Scheme 45), the purine nucleophile could attack a chlorine 
atom in the instead of a bromine atom, eliminating either a bromine or chlorine atom in the 
process. This could be caused by the presence of a bulky substituent on the 9-position, making 
the smaller chlorine atom more sterically favourable for this substrate. This yields the 
chlorinated product (8) directly.  
The second suggested mechanism is that the attack on the bromine atom could occur while the 
haloethane is in a less favourable Gauche conformation and result in the elimination of a 
chlorine atom. This free chlorine nucleophile is free to then attack the brominated compound 
and carry out nucleophilic aromatic substitution, also giving the chlorinated product (Scheme 
46). 
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It is worth noting that bromination using the lithiation capture-method has been carried out in 
the Gundersen group at UiO on the less sterically-hindered 9-methyl- and 9-ethyladenines.
84
 
In the first case, no chlorination was observed, but for the ethyl substrate, 8-10% of the 
chlorinated product was reported. It may be that sterical factors play a part in this mechanism 
– pointing to the situation in Scheme 45 as being more likely. 
Since no mechanistic studies have been carried out on this reaction, no conclusions will be 
drawn in this work. However, it is a consideration to be aware of, if one uses 
dibromotetrachloroethane as a brominating agent. In our project, the presence of the 
chlorinated product (8b and 8c) did not affect the outcome, since both the chlorine and 
bromine act as good leaving groups in the hydrolysis step. The approximate isolated yields of 
the bromination reactions (calculated from NMR) are given in Table 11. 
Table 11. Results of bromination using tetrachlorodibromoethane. 
Entry R Ratio 6:8 6:8  
[%] 
Total yield 
[%] 
1  b: Cyclopentyl 10:2 62:12 ~74 
2 c: Cyclohexylmethyl 10:4 57:23 ~66 
 
4.4.2. Attempted Optimisation of the Reaction Conditions using 9-Cyclopentyladenine 
To simplify matters, it was decided to try different electrophilic species that could only donate 
one species of halogen atom. In addition, since conversion was less than 100% in the original 
reactions, a few different sets of conditions were tried out. The chosen substrate was the 
cyclopentyl analogue and the results are set out in Table 12. 
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Scheme 47. General reaction for lithiation/halogentaion of 9-cyclopentyladenine (7b). 
Table 12. Conditions used for optimisation of the reaction shown in Scheme 47. 
Entry Electrophile 
source 
“E+” LDA 
[eq] 
t  
(step 1) 
[h] 
t  
(step 2) 
[h] 
Approximate 
conversion (NMR) 
[%] 
Yield 
[%]  
1 BrCl2CCCl2Br Br/Cl 2.8  1 4 60 ~53 
2 BrCl2CCCl2Br Br /Cl 5  1 4 75 ~74 
3 NBS Br 5  1 4 80 65 
4 NBS Br 5  2 4 80 57 
5 NBS Br 5  1 20 
(to r.t.) 
75 60 
6 C2Cl6 Cl 5  1 4 87 69 
7 C2Cl6 Cl 10  1 4 78 86 
 
From Entries 2 to 6 in Table 12, it can be observed that the approximate conversions and 
yields remain around the same area (70-80% and 60-70%, respectively). In the end, it was 
decided to use 5 eq LDA and hexachloroethane as the electrophile donor. The reasons for this 
were several.  
Firstly, the by-product of using NBS, succinimide, proved more difficult to remove than the 
by-product of the other two reagents, tetrachloroethene. It eluted in flash chromatography 
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with similar retention as both the product and starting material, and required an additional 
aqueous work-up.  
In comparison, tetrachloroethene has a boiling point of 121 ˚C and is extremely non-polar. 
This means that it is easy to separate from both the product and starting material if it is not 
already removed during evaporation of the solvent and concentration of the reaction mixture. 
Secondly, it had been found previously that neither a longer lithiation nor reaction time 
appeared to affect the outcome, nor did allowing the reaction temperature to increase to 
ambient temperature overnight.  
Finally, the amount LDA used was retained at 5 eq, despite Entry 7 perhaps indicating that 
yields could be improved. Entry 7 is slightly suspicious as the yield obtained was higher than 
the conversion indicated by crude NMR spectroscopy. The source of this discrepancy is 
unknown but in hindsight it would have been desirable to repeat this experiment to ascertain if 
this yield is reproducible. The NMR spectrum itself was not a very good one, and the 
conversion indicated may have been misleading. 
This decision was, in the end, made for two reasons: the conversion indicated on NMR had 
not improved significantly and it seemed preferable to use the group’s standard amount of 
LDA for adenine, which is 5 eq. This would allow results obtained in this project to be 
comparable. This decision in retrospect may be deserving of criticism. 
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4.4.3. Lithiation and Capture with Hexachloroethane  
The final scheme for the adenine-derivatives (7) looked therefore as shown in Scheme 48. 
 
Scheme 48. Final standard conditions for lithiation and halogenation used in this thesis. 
The standardised method was then carried out on all adenine substrates and after aqueous 
work-up were further purified with a flash system that seemed to give a good balance of 
solubility and separation. The halogenated products were obtained in moderate yields and 
consistent yields. The results are presented in Table 13. 
Table 13. Results for chlorination via lithiation for the different 9-substituted adenine substrates (7). 
Entry R Yield (halogenation) [%] 
1  a: Benzyl Debenzylation  
2 b: Cyclopentyl 69 
3 c: (Cyclohexyl)methyl 68 
4 d: Phenyl 67 
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One interesting result is that seen for attempting lithiation and chlorination with  
9-benzyladenine (Table 13, Entry 1). Instead of a clean reaction, as seen for the other 
substrates, the products isolated here included (but were not limited to) starting material 
(~14%), product (<10%), adenine (~12%) and benzaldehyde (trace), all impure.  
Debenzylation of nitrogens has been widely reported – not all methods are described here. 
One route is to carry out acid hydrolysis with trifluoroacetic acid – used in fact in this project 
to cleave a 4-methoxybenzyl group (see Section 3.4.4).
81
 Hydrogenolysis with palladium or 
carbon is another known method.
86
 It has been also been reported that a strong base and 
oxygen can be employed to carry out debenzylation.
86-89
  
An earlier Masters student in the Gundersen group at UiO, Thywill Gamadeku, has suggested 
two mechanisms as the explanation for observations of debenzylation when lithiating and 
brominating 9-benzylated purines.
85
 The first is taken from an article by Suzuki – where the 
deprotonation occurs on the benzylic methylene which then undergoes α-elimination and 
oxidative debenzylation to give the debenzylated product (after aqueous work-up) and a 
carbene. The carbene is then attacked by the original anion and decomposes to give trans-
stilbene. The second suggestion made by Gamadeku was that it is the presence of the halogen 
that causes the debenzylation process to occur.  
In the course of the current project, it was decided to carry out two experiments to investigate 
possible causes of the debenzylation. The first was to quench the reaction after the lithiation 
step with saturated ammonium chloride solution – this returned to quantitative amount of 
starting material and no indications of debenzylation. The second experiment was a 
deuteration experiment also carried out after the lithiation step. This experiment indicated that 
both the H-8 and one of the N-CH2 protons are acidic enough to be deprotonated in the first 
step (with the H-8 being deprotonated to a greater extent). This indicated that it was not 
merely the presence of the base that caused debenzylation in the current experiment, but the 
addition of the halogenating agent (as suggested by Gamadeku).
85
 It is proposed that a 
mechanism like the one presented in Scheme 49 may explain the debenzylation as a result of 
halogenation on the benzylic position. 
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Scheme 49. Proposed mechanism for lithiation, chlorination and debenzylation. 
The experiment provides a warning that carrying out deprotonation with a strong base like 
LDA on compounds containing side-chains with relatively acidic protons can provide the 
opportunity for unexpected and possibly unstable side-products. In cases where the benzylic 
methylene protons are the only acidic protons, the halogenation of this position may provide 
an efficient method to debenzylate. This remains to be seen and unfortunately fell outside the 
scope of this project. 
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4.5. Halogenation of 9-Substituted 6-Chloropurine  
The lithiation and halogenation procedure was also carried out on 6-chloro-9-phenylpurine 
(14), but with fewer equivalents of LDA (1.4 eq), less brominating compound (2 eq) and 
shorter reaction time (2 h) (Scheme 50). This gave a pleasing 100% conversion on crude 
NMR, with ~5% by-product.  
 
Scheme 50. Lithiation and halogenation of 6-chloro-9-phenylpurine (14). 
However, upon flashing the crude mixture, it was discovered that the desired product did not 
tolerate silica. When the crude mixture was evaporated onto silica, the yield was only 46%. 
When applied as a suspension to the column, it increased to 61%. Using an aluminium oxide 
column had the effect of making the separation of the compounds worse due to poor solubility 
of the compounds at the lower polarity eluents. Recrystallization of the crude was also 
attempted with some limited success, reducing the amount of by-product was reduced from 
5% to 1%.  
If this compound was to be used as an intermediate for further reactions, it could be advisable 
to carry out further transformations on the crude product before purification. The by-product 
was obtained only as an impure mixture. Mass spectroscopy and NMR studies indicated that 
what was produced was a dimer with an iso-propylamino group attached. Below is shown a 
suggested structure and mechanism for the creation of a possible by-product fitting these 
criteria (Scheme 51). 
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Scheme 51. Possible by-product of lithiating and brominating 6-chloro-9-phenylpurine (14). 
Of course, this route has no place in the synthesis of 9-phenyl-8-oxoadenine as the method 
used for the next amination step (heating in ammonium hydroxide) would be expected to be 
unselective between the 6- and 8-positions. This experiment was run anyway to see if there 
was a difference and the result was two monoaminated products in a 1:1 ratio and ~90% yield 
(Figure 21). Full characterisation was attempted on this mixture, but overlapping signals did 
not allow for identification with complete certainty.  
 
Figure 21. The two products from amination of 8-bromo-6-chloro-9-phenylpurine (44). 
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Perhaps this compound could be used as a precursor for a reaction where the identity of the 
halogen is important – for example, a coupling reaction. Finally it should be noted that no 
chlorinated compound was obtained in this experiment. The reason for this is unknown but is 
perhaps related to the amount of LDA required for deprotonating the adenine substrates. 
4.5.1. Hydrolysis of 8-Halo-9-substituted Adenines 
The 8-chloro-9-substituted adenines (8) obtained were hydrolysed following the same 
procedure as used for the hydrolysis of the 8-bromo-9-substituted adenines (6) (see Sections 
3.24 and 3.4.5). The mixture of compounds 6b and 8b and that of 6c and 8c were also 
hydrolysed. The results of all the hydrolysis reactions are summarised in Table 14. 
Table 14. Results of hydrolysis of compounds 6 and 8. 
Entry R Yield  
(Mixture of 8-Br and 8-Cl) 
[%] 
Yield  
(8-Cl)  
[%] 
Yield  
(8-Br)  
[%] 
1 a: Benzyl N/A N/A 85 
2 b: Cyclopentyl ~92% 
(yield over two steps = 72%) 
92 89 
3 c: (Cyclohexyl)methyl ~94% 
(yield over two steps = 65%) 
90 78 
4 d: Phenyl N/A 73 N/A 
  
It appears that the substrates that are amenable to this transformation give nearly identical 
yields. There are no clear trends in the hydrolysis results, but it is indicative that the identity 
of the halogen species is not essential for this reaction. One additional result that was 
interesting was that a small amount of by-product was isolated from the hydrolysis of the 
cyclohexylmethyl and phenyl analogues (4% for both compounds).  
These by-products appeared to have three protons attached to heteroatoms (with some kind of 
tautomerism occurring in solution) and a molecular mass that was in agreement with the 
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amino group of the product reacting with one molecule of formic acid to give the proposed 
compound below (Scheme 52). Unfortunately, despite a great many attempts to characterise 
these compounds via different NMR techniques and at higher fields, the structures of these 
compounds were not able to be fully elucidated. However, MS does support these 
conclusions. The incomplete data is included in the experimental section.  
If we consider that we have already commented that diaminated compounds can be ring-
closed with carboxylic acid derivatives (see Section 2.5), including formic acid,
28
 the 
suggestion that formic acid reacts with the free amino group in this reaction is unsurprising. If 
one desired to remove this possibility, another type of acid could be utilised. 
 
Scheme 52. Mechanism of creation of a possible by-product of the hydrolysis of compounds 8c and 
8d. 
4.6. Conclusions 
Treatment of these four 9-substituted adenines and one 9-substituted 6-chloropurine shows 
that this method gives moderate yields for the halogenation reaction (60 – 70%) and good to 
excellent yields for the hydrolysis step. It also shows that choice of the halogen donor is 
important and some donor may cause the production of unwanted by-products or more 
difficult purification of the crude product. Hydrolysis works well for both chlorinated purines 
and brominated purines. Compared to brominating with liquid bromine and NBS, this method 
gives comparable yields and has a shorter reaction time. However, the requirements of inert 
atmosphere, low temperatures and aqueous work-up result in some additional work for 
halogenation via lithiation.  
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CHAPTER 5 
5. BIOLOGICAL TESTING 
5.1. General 
Testing of the four target compounds has been carried out at were at the Institute for Clinical 
Biochemistry and Institute for Medical Microbiology at the National Hospital in Oslo. At the 
time of writing, testing had been partly completed and this involved assays with the enzyme 
human alkyladenine DNA glycosylase (hAAG). Testing is also planned for assays with the 
enzyme human 8-hydroxyguanine DNA glycosylase (hOGG1). The compounds and some of 
the intermediates were also tested for some viral activity at a different institute. 
5.2. Testing on Human DNA Glycosylases 
As mentioned earlier, DNA glycosylases are enzymes that are responsible for identifying and 
excising specific lesion basses from the DNA strand. The two glycosylases that are most 
likely to identify our target molecules as damaged bases and show inhibitory effects are 
hAAG and hOGG1. Human alkyladenine DNA glycosylase (hAAG) (Figure 22) is a human 
enzyme which recognises damaged bases in DNA and partakes in base excision repair of a 
diverse selection of substrate bases including alkylated adenines, hypoxanthine and etheno 
bases.
7,12,13
 It was decided to test for inhibition of this enzyme because the molecules made in 
this project were alkylated adenine-derivatives. 
 
Figure 22. Crystal structure of a hAAG complex with DNA. 
The base (shown in black) is being flipped into the active site 
of the glycosylase.
7 
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None of the four compounds tested displayed any visible inhibitory effect on enzyme activity 
of hAAG at 1 mM concentration. DNA with inosine was used as the substrate for the testing 
and the same amount of cutting of the DNA was observed to be carried out by the enzyme 
with 1 mM concentration of the compounds as the control test with only the enzyme present. 
Recently, the crystal structure of hAAG bound to 3,N
4
-ethenocytosine lesions has been 
elucidated. It has been found that this particular lesion inhibits the activity of the enzyme 
because hAAG fails to activate the nucleotide base as an efficient leaving group and carry out 
excision. The structure of the active site of the enzyme from this study could provide 
interesting information for the design of hAAG inhibitors in the future.
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Human 8-hydroxyguanine DNA glycosylase (hOGG1) the main DNA glycosylase that 
excises the oxidative lesion, 8-oxoguanine, and initiates base excision repair. Since 8-
oxoguanine is a common lesion is known to cause mismatches, for example with adenine, and 
results in mutations, this repair enzyme is extremely important for cell repair. This also makes 
it a good target for inhibition of repair in cancer cells.
91,92
 
It has also been reported that this enzyme is responsible for the repair of some 8-oxoadenine 
lesions depending on whether they are pair with a cytosine or guanine base.
8
 The 
identification of 8-oxoadenine and 8-oxoguanines is the reasons that this enzyme has been 
chosen for biological testing. 
5.3. Virus Testing 
Some of the intermediates and final compounds were also tested for viral activity against a 
broad panel of viruses. Unfortunately, there were no hits among the compounds synthesised in 
this thesis. The compounds tested were the four target molecules, 3- and 9-benzyl-8-
bromoadenine and 3-benzyl-8-oxoadenine. The viruses for which assays were carried out are 
listed in Appendix 2). 
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CHAPTER 6 
6. CONCLUSIONS AND FURTHER WORK 
6.1. General 
The development of medicinal drugs to promote the selective effectiveness of cancer 
treatment through exploitation of features specific to cancer cells can be a key to the success 
of the overall cancer therapy. By targeting the actions of specific enzymes that carry out 
repair on lesions created on DNA in cancer cells, the ability of these cells ability to survive 
radiation therapy or chemotherapy can be reduced or removed completely. The focus of this 
project was to synthesise the target molecules for testing, employing various synthetic 
strategies, which has been accomplished. A summary of the overall yields for all routes 
discussed in the current project is shown in Table 15. 
Table 15. Overview of the best overall results from the syntheses carried out. 
 Br2: bromination with liquid bromine, RX: alkylation with alkyl halide and base, O: acid-catalysed 
hydrolysis, LDA: lithiation and capture with C2X2Cl4. a) debenzylation observed in halogentaion 
step; b) insufficient material obtained after second (alkylation) step to complete the scheme. 
Entry R 
S
tr
at
eg
y
 1
  
(B
r 2
, 
R
X
, 
O
) 
S
tr
at
eg
y
 2
  
(B
r 2
, 
O
, 
R
X
) 
S
tr
at
eg
y
 3
  
(R
X
, 
B
r 2
, 
O
) 
S
tr
at
eg
y
 4
  
(f
ro
m
 p
y
ri
m
id
in
e)
 
S
tr
at
eg
y
 5
  
( 
fr
o
m
 6
-c
h
lo
ro
p
u
ri
n
e)
 
S
tr
at
eg
y
 6
  
(R
X
, 
L
D
A
, 
O
) 
B
es
t 
o
v
er
a
ll
 y
ie
ld
 
(S
tr
a
te
g
y
) 
1 Benzyl (3a) 9 6 19 N/A N/A -
a) 
19 (3) 
2 Cyclopentyl 
(3b) 
N/A 12 37 N/A N/A 46 
(C2Br2Cl4) 
46 (6) 
3 Cyclohexyl-
methyl (3c) 
- 
b) 
12 42 N/A N/A 50 
(C2Br2Cl4) 
50 (6)  
4 Phenyl (3d) N/A N/A N/A 50 33 
(C2Cl6) 
50 (4) 
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The synthetic routes used have involved an investigation of the possibilities of functionalising 
commercially-available purines, adenine and 6-chloropurine, and formation of the purine ring 
system from commercially available 4,6-dichloro-5-aminopyrimidine. The main challenges 
met during the project were encountered in the alkylation and arylation steps and factors that 
contributed to this include the polarity of the adenines increasing the difficulty of separation 
in purification and the regioselectivity of the alkylation steps.  
Good overall yields were obtained for 3b and 3c through Strategy 6 (alkylation, treatment 
with LDA and dibromotetrachloroethane and hydrolysis). Strategy 3 also gave yields which 
were not much worse, which indicates that the difference in the bromination step is small 
since the first and third steps are the same in these two strategies. For compound 3d, the best 
strategy was that starting from a pyrimidine derivative (Strategy 4). Despite the route having 4 
steps, the overall yield was still reasonably good. Compound 3a fared the worst of the 
analogues with an overall yield of 19%, also from Strategy 3. 
Strategy 4 is perhaps the synthesis route which could be interesting to pursue – for example, if 
we desired higher overall yields for compounds 3. Following the pathway of aminating 4,6-
dichloro-5-aminopyrimidine, treatment with CDI and amination, seems to be an elegant 
method to regioselectively obtain the target molecules by taking advantage of symmetry in the 
amination step. 
If further analogues were to be synthesised for biological testing, it could be interesting to 
synthesize analogues with substituents on the aromatic rings or perhaps non-ring substituents. 
The current thesis has provided some exploration of the possibilities of obtaining 9-
substituted-8-oxoadenines while obtaining the target molecules for biological testing.  
Another future prospect for this project is the syntheses of 9-substituted-8-oxoguanines for 
biological testing and it is hoped that some of the results and methods obtained in the course 
of this project can be carried on to facilitate smoother synthesis of these compounds. In 
addition, as mentioned in Section 3.1, it could be an interesting, separate project to carry out a 
thorough survey of the alkylating patterns of different 8-substituted adenines or purines, with 
a variety of alkylating agents, to gain an overview of substitution patterns and give further 
insight into the possibilities of functionalising the purine ring. 
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CHAPTER 7 
7. EXPERIMENTAL 
 
The 1H NMR spectra were recorded at 600 MHz with a Bruker AV 600, at 500 MHz with a 
Bruker Advance DRX 500 instrument, at 400 MHz with a Bruker DPX 400, 300 MHz with a 
Bruker DPX 300 or at 200 MHz with a Bruker DPX 200 instrument. The 13C NMR spectra 
were recorded at 150, 125, 100 or 75* MHz using the above-mentioned instruments. Mass 
spectra were recorded on a VG Prospec sector instrument from Fissions Instrument at 70 eV 
ionizing voltage and are presented as m/z (% rel. int.).  
DMF and THF were obtained from a solvent purification system, MB SPS-800 from Mbraun, 
before each reaction and TMEDA was distilled over KOH. Ethyl acetate, hexanes and 
dichloromethane were distilled before use. All other reagents were commercially available 
and used as received. n-BuLi was titrated with menthol using 1,10-phenanthroline as an 
indicator. Diisopropylamine was stirred over sodium hydroxide for at least 24 h, vacuum-
distilled over calcium hydride and stored over molecular sieves. Lianne Hill, School of 
Chemistry University of Birmingham, England, carried out the elemental analyses. 
Melting points were determined with a Büchi melting point B-545 apparatus and are uncorrected. 
Some of the by-products were obtained only impure or in an insufficient amount to carry out 
melting point measurements. These are labelled “not obtained”.   
 
 
 
 
* In all 
13
C spectra taken at 75 MHz, there is a peak that is positive and negative, present at 
approximately 79-80 ppm. This is due to noise from the NMR instrument. 
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8-Bromo-9H-purin-6-amine (5) 
 
Adenine (4) (5.265 g, 38.96 mmol) and liquid bromine (15 mL) was kept in a closed flask for 
4 h, before the stopper was removed. The mixture was allowed to stand overnight, before the 
resulting solid was stirred in water (50 mL). Concentrated aqueous ammonia was added until 
dissolution and the solution neutralised with acetic acid. The precipitate was filtered, washed 
with water, then boiled in water and filtered while hot (washed with water, acetone and ether), 
then dried in vacuo. Yield 6.201 g (74%) beige solid. 
1H NMR (DMSO-d6, 300 MHz):  13.59 (br s, 1H, NH), 8.09 (s, 1H, H-2), 7.41 (s, 2H, 
NH2). 
13C NMR (DMSO-d6, 75 MHz):  154.0 (C-4 or C-6), 152.1 (C-4 or C-6), 150.0 (C-2), 
127.6 (C-8), 119.9 (C-5). 
MS EI m/z (rel. %): 215/213 (100/97, M+), 186/188 (36/35), 107 (27).  
HR-MS Found 212.9646, calculated for C5H4N5Br 212.9650. 
M.p. > 260 oC (decomposed) (lit.
58
 > 250 oC).  
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Spectrum 6. 1H NMR of 8-Bromo-9H-purin-6-amine (5). 
 
Spectrum 7. 13C NMR of 8-Bromo-9H-purin-6-amine (5). 
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Spectrum 8. HSQC of 8-Bromo-9H-purin-6-amine (5). 
 
Spectrum 9. HMBC of 8-Bromo-9H-purin-6-amine (5). 
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Spectrum 10. HMBC of 8-Bromo-9H-purin-6-amine (5), expansion of the aromatic region. 
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6-Amino-7H-purin-8(9H)-one (2a) 
 
8-Bromoadenine (5) (439 mg, 2.05 mmol) was refluxed in formic acid (50 mL) for 24 h and 
compound 2a recrystallized from water as a beige powder (190 mg, 58%).  
1H NMR (DMSO-d6, 400 MHz): δ 11.23 (s, 1H, NH), 9.87 (s, 1H, NH), 7.94 (s, 1H, H-2), 
6.31 (s, 2H, CH2). 
13C NMR (DMSO-d6, 100 MHz): 152.7 (C-8), 150.8 (C-2), 148.0 (C-4 or C-6), 146.3 (C-4 
or C-6), 104.3 (C-5). 
MS EI m/z (rel. %): 151 (100, M
+
), 124 (7), 97 (6). 
HR-MS Found 151.0490, calculated for C5H5N5O 151.0494. 
M.p. > 250 °C (decomposed). 
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Spectrum 11. 1H NMR of 6-Amino-7H-purin-8(9H)-one (2a). 
 
Spectrum 12. 13C APT NMR of 6-Amino-7H-purin-8(9H)-one (2a). 
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Spectrum 13. HSQC of 6-Amino-7H-purin-8(9H)-one (2a). 
 
Spectrum 14. HMBC of 6-Amino-7H-purin-8(9H)-one (2a). 
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Spectrum 15. HMBC of 6-Amino-7H-purin-8(9H)-one (2a), expansion of the aromatic region. 
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9-Benzyl-9H-purin-6-amine (7a) and 3-Benzyl-3H-purin-6-amine (28a) 
 
A mixture of adenine (4) (271 mg, 2.01 mmol), DMF (10 mL) and potassium carbonate  
(552 mg, 3.99 mmol) was stirred under an argon atmosphere. Benzyl bromide (0.30 mL,  
2.5 mmol) was added and the mixture stirred at the same temperature for 4 h. The mixture 
was filtered and the solvent evaporated in vacuo. The residue was purified by column 
chromatography (0-10% methanol in dichloromethane) to give compounds 7a (241 mg, 53%) 
and 28a (102 mg, 23%) as colourless powders. 
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9-Benzyl-9H-purin-6-amine (7a) 
 
1H NMR (DMSO-d6, 200 MHz): 8.24 (s, 1H, H-8), 8.14 (s, 1H, H-2), 7.30 – 7.24 (m, 5H, 
H-12, H-13 and H-14), 7.24 (br s, 2H, NH2), 5.35 (s, 2H, H-10). 
13C NMR (DMSO-d6, 75 MHz): 
 156.0 (C-6), 152.6 (C-2), 149.5 (C-4), 140.8 (C-8), 137.1 
(C-11), 128.6 (C-13), 127.7 (C-14), 127.5 (C-12), 118.7 (C-5), 46.1 (C-10). 
MS EI m/z (rel. %): 225 (79, M
+
), 224 (100), 182 (15), 148 (8), 91(82), 65 (17). 
HR-MS Found 225.1010, calculated for C12H11N5 225.1014. 
M.p. 233-235 °C (lit.
93
 = 231-234 °C). 
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Spectrum 16. 1H NMR of 9-Benzyl-9H-purin-6-amine (7a). 
 
Spectrum 17. 13C NMR of 9-Benzyl-9H-purin-6-amine (7a). 
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Spectrum 18. 13C NMR of 9-Benzyl-9H-purin-6-amine (7a), expansion of the aromatic region. 
 
Spectrum 19. HMQC of 9-Benzyl-9H-purin-6-amine (7a). 
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Spectrum 20. HMBC of 9-Benzyl-9H-purin-6-amine (7a). 
 
Spectrum 21. HMBC of 9-Benzyl-9H-purin-6-amine (7a), expansion of aromatic and benzylic region. 
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3-Benzyl-3H-purin-6-amine (28a) 
 
1H NMR (DMSO-d6, 500 MHz) δ 8.54 (s, 1H, H-2), 7.96 and 7.87 (br d, 2H, NH2), 7.74  
(H-8), 7.45 – 7.44 (d, 2H, H-12), 7.34 – 7.27 (m, 3H, H-13 and H-14), 5.50 (s, 2H, H-10). 
13C NMR (DMSO-d6, 125 MHz) δ 154.9 (C-6), 152.6 (C-8), 149.7 (C-4), 143.3 (C-2), 136.1 
(C-11), 128.6 (C-12 or C-13), 128.04 (C-12 or C-13), 127.99 (C-14), 120.5 (C-5), 52.1  
(C-10). 
MS EI m/z (rel. %): 225 (44, M
+
), 224 (100), 91 (72), 65 (12). 
HR-MS Found 225.1006, calculated for C12H11N5 225.1014. 
M.p. 265-268 °C 
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Spectrum 22. 1H NMR of 3-Benzyl-3H-purin-6-amine (28a). 
 
Spectrum 23. 13C NMR of 3-Benzyl-3H-purin-6-amine (28a). 
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Spectrum 24. 13C NMR of 3-Benzyl-3H-purin-6-amine (28a), expansion of the aromatic region and 
expansion of region showing phenyl signals (inset). 
 
Spectrum 25. HSQC of 3-Benzyl-3H-purin-6-amine (28a). 
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Spectrum 26. HMQC of 3-Benzyl-3H-purin-6-amine (28a). 
 
 
Spectrum 27. HMBC of 3-Benzyl-3H-purin-6-amine (28a), expansion of the benzylic and aromatic 
region. 
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9-Cyclopentyl-9H-purin-6-amine (7b) and 3-Cyclopentyl-3H-purin-6-amine (28b) 
 
A mixture of adenine (4) (548 mg, 4.06 mmol), DMF (20 mL) and potassium carbonate  
(1117 mg, 8.082 mmol) was stirred at 65 °C under a nitrogen atmosphere for 30 minutes. 
Bromocyclopentane (0.81 mL, 7.6 mmol) was added and the mixture stirred at the same 
temperature for another 72 h. The mixture was filtered and the solvent evaporated in vacuo. 
The residue was purified by column chromatography (0-10% methanol in dichloromethane) to 
give 7b as a colourless powder (720 mg, 70%) and 28b (72.3 mg, 7%, after recrystallization 
with chloroform/hexanes) as colourless crystals. 
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9-Cyclopentyl-9H-purin-6-amine (7b) 
 
1
H NMR (DMSO-d6, 300 MHz) δ 8.18 (s, 1H, H-2), 8.11 (s, 1H, H-8), 7.13 (s, 2H, NH2), 
4.81 (p, J = 7.5 Hz, 1H, H-10), 2.22 – 1.42 (m, 8H, H-11 and H-12).  
13
C NMR (DMSO-d6, 75 MHz) δ 156.0 (C-6), 152.2 (C-2), 149.4 (C4), 139.3 (C-8), 119.2 
(C-5), 55.3 (C-10), 31.9 (C-11), 23.5 (C-12). 
MS EI m/z (rel. %) 203 (47, M
+
), 162 (48), 135 (100), 108 (36), 67 (7). 
HR-MS Found 203.1167, calculated for C10H13N5 203.1171. 
M.p. 155-157 °C (lit.
69
 = 154 °C).  
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Spectrum 28. 1H NMR of 9-Cyclopentyl-9H-purin-6-amine (7b). 
 
Spectrum 29. 13C NMR of 9-Cyclopentyl-9H-purin-6-amine (7b). 
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Spectrum 30. HMQC of 9-Cyclopentyl-9H-purin-6-amine (7b). 
 
Spectrum 31. HMBC of 9-Cyclopentyl-9H-purin-6-amine (7b). 
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Spectrum 32. HMBC of 9-Cyclopentyl-9H-purin-6-amine (7b), expansion of the aromatic region. 
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3-Cyclopentyl-3H-purin-6-amine (28b) 
 
1
H NMR (DMSO-d6, 300 MHz) δ 8.36 (s, 1H, H-2), 7.88 (s, 2H, NH2), 7.76 (s, 1H, H-8), 
4.99 (p, J = 8.1 Hz, 1H, H-10), 2.38 – 1.36 (m, 8H, H-11 and H-12).  
13
C NMR (DMSO-d6, 75 MHz) δ 155.7 (C-6), 153.1 (C-8), 150.1 (C-4), 142.9 (C-2), 121.6 
(C-5), 62.6 (C-10), 31.5 (C-11), 25.8 (C-12).  
MS EI m/z (rel. %) 203 (23, M
+
), 162 (30), 135 (100), 108 (28), 67 (7).  
HR-MS Found 203.1167, calculated for C10H13N5 203.1171. 
M.p. 209-210 °C. 
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Spectrum 33. 1H NMR of 3-Cyclopentyl-3H-purin-6-amine (28b). 
 
Spectrum 34. 13C NMR of 3-Cyclopentyl-3H-purin-6-amine (28b). 
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Spectrum 35. HMQC of 3-Cyclopentyl-3H-purin-6-amine (28b). 
 
Spectrum 36. HMBC of 3-Cyclopentyl-3H-purin-6-amine (28b). 
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9-(Cyclohexylmethyl)-9H-purin-6-amine (7c) and 3-(Cyclohexylmethyl)-3H-purin-6-
amine (28c) 
  
A mixture of adenine (4) (135 mg, 1.00 mmol), DMF (5 mL) and potassium carbonate  
(314 mg, 2.28 mmol) was stirred at 65 °C under a nitrogen atmosphere for 30 minutes. 
(Bromomethyl)cyclohexane (0.21 mL, 1.5 mmol) was added and the mixture stirred at the 
same temperature for another 72 h. The mixture was filtered and the solvent evaporated in 
vacuo. The residue was purified by column chromatography (0-10% methanol in 
dichloromethane) to give 7c as a pale yellow powder (165 mg, 71%) and 28c (30 mg, 13%) as 
a colourless powder.  
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9-(Cyclohexylmethyl)-9H-purin-6-amine (7c) 
 
1
H NMR (DMSO-d6, 600 MHz) δ 8.13 (s, 1H, H-2), 8.10 (s, 1H, H-8), 7.18 (s, 2H, NH2), 
3.96 (d, J = 7.2 Hz, 2H, H-10), 1.83 (dtt, J = 14.8, 7.4, 3.7 Hz, H-11), 1.64 – 1.47 (m, 5H,  
H-12, H-13 and H-14,), 1.18 – 0.85 (m, 5H, H-12, H-13 and H-14).  
13
C NMR (DMSO-d6, 150 MHz) δ 156.0 (C-6), 152.3 (C-2), 149.9 (C-4), 141.3 (C-8), 118.9 
(C-5), 48.7 (C-10), 37.5 (C-11), 30.0 (C-12), 25.8 (C-14), 25.0 (C-13).  
MS EI m/z (rel. %) 231 (72, M
+
), 188 (12), 149 (100), 148 (76), 136 (22), 135 (80), 108 (15). 
HR-MS Found 231.1478, calculated for C12H17N5 231.1484. 
M.p. 224-226 °C. 
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Spectrum 37. 1H NMR of 9-(Cyclohexylmethyl)-9H-purin-6-amine (7c). 
 
Spectrum 38. 13C NMR of 9-(Cyclohexylmethyl)-9H-purin-6-amine (7c). 
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Spectrum 39. HSQC of 9-(Cyclohexylmethyl)-9H-purin-6-amine (7c). 
 
Spectrum 40. HMBC of 9-(Cyclohexylmethyl)-9H-purin-6-amine (7c). 
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Spectrum 41. HMBC of 9-(Cyclohexylmethyl)-9H-purin-6-amine (7c), expansion of the aromatic 
region. 
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3-(Cyclohexylmethyl)-3H-purin-6-amine (28c) 
 
1
H NMR (DMSO-d6, 600 MHz) δ 8.29 (s, 1H, H-2), 7.98 and 7.92 (br d, 2H, NH2), 7.77 (s, 
1H, H-8), 4.12 (d, J = 7.4 Hz, 2H, H-10), 2.01 (dtt, J = 15.0, 7.5, 3.8 Hz, H-11), 1.63 – 1.45 
(m, 5H, H-12, H-13 and H-14), 1.10 – 0.97 (m, 5H, H-12, H-13 and H-14).  
13
C NMR (DMSO-d6, 150 MHz) δ 155.0 (C-6), 152.3 (C-2), 149.8 (C-4), 143.9 (C-8), 120.2 
(C-5), 55.1 (C-10), 36.4 (C-11), 29.8 (C-12), 25.9 (C-14), 25.1 (C-13).  
MS EI m/z (rel. %) 231 (72, M
+
), 188 (12), 149 (100), 148 (76), 136 (22), 135 (80), 108 (15). 
HR-MS Found 231.1479, calculated for C12H17N5 231.1484. 
M.p. 250-252 °C.  
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Spectrum 42. 1H NMR of 3-(Cyclohexylmethyl)-3H-purin-6-amine (28c). 
 
Spectrum 43. 13C NMR of 3-(Cyclohexylmethyl)-3H-purin-6-amine (28c). 
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Spectrum 44. HSQC of 3-(Cyclohexylmethyl)-3H-purin-6-amine (28c). 
 
Spectrum 45. HMBC of 3-(Cyclohexylmethyl)-3H-purin-6-amine (28c). 
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Spectrum 46. HMBC of 3-(Cyclohexylmethyl)-3H-purin-6-amine (28c), expansion of the aromatic 
region. 
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6-Chloro-9-phenyl-9H-purine (14) 
 
6-Chloropurine (13) (152 mg, 1.05 mmol), phenylboronic acid (371 mg, 3.04 mmol),  
1,10-phenanthroline (366 mg, 2.03 mmol), anhydrous copper(II) acetate (188 mg, 1.04 mmol) 
and 982 mg 3Ǻ molecular sieves were weighed into a flask. Dry DCM (15 mL) was added, a 
condenser attached and the reaction mixture stirred at ambient temperature in open 
atmosphere for 4 days. Methanol (150 mL) was added and the mixture was filtered through 
Celite, evaporated and purified by flash chromatography (1:3 ethylacetate:hexanes) to give 14 
as a white powder (147 mg, 72%). 
1
H NMR (DMSO-d6, 400 MHz) δ 9.11 (s, 1H, H-8), 8.84 (s, 1H, H-2), 7.89 (d, J = 7.9 Hz, 
2H, H-11), 7.64 (t, J = 7.7 Hz, 2H, H-12), 7.53 (t, J = 7.3 Hz, 1H, H-13). 
13
C NMR (DMSO-d6, 100 MHz) δ 152.2 (C-2), 151.5 (C-4), 149.6 (C-6), 146.4 (C-8), 134.0 
(C-10), 131.5 (C-5), 129.6 (C-12), 128.5 (C-13), 123.7 (C-11). 
MS EI m/z (rel. %) 232/230 (32/100, M
+
), 195 (14), 168 (12), 141 (7), 77 (16). 
HR-MS Found 230.0356, calculated for C11H7ClN4 230.0359. 
M.p. 250-252 °C.  
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Spectrum 47. 1H NMR of 6-Chloro-9-phenyl-9H-purine (14). 
 
Spectrum 48. 13C NMR of 6-Chloro-9-phenyl-9H-purine (14). 
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Spectrum 49. HSQC of 6-Chloro-9-phenyl-9H-purine (14). 
 
Spectrum 50. HSQC of 6-Chloro-9-phenyl-9H-purine (14), expansion of the aromatic region. 
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Spectrum 51. HMBC of 6-Chloro-9-phenyl-9H-purine (14). 
 
Spectrum 52. HMBC of 6-Chloro-9-phenyl-9H-purine (14), expansion of the aromatic region. 
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9-Phenyl-9H-purin-6-amine (7d) and 7-Phenyl-7H-purin-6-amine (29d) 
  
Method 1 (from adenine): A mixture of adenine (4) (70 mg, 0.52 mmol), phenylboronic acid 
(136 mg, 1.12 mmol), copper(II) acetate monohydrate (101 mg, 0.506 mmol) and TMEDA 
(0.15 mL, 1.0 mmol) was stirred vigorously in a mixture of 10 mL distilled water and 40 mL 
methanol for 21.5 h at ambient temperature. The solvent was evaporated in vacuo and the 
residue purified by column chromatography (2.5-10% methanol in dichloromethane) to give 
7d as a colourless powder (22 mg, 20%).  
Method 2 (from adenine): A mixture of adenine (4) (135 mg, 1.00 mmol), phenyl boronic acid 
(184 mg, 1.51 mmol), 1,10-phenanthroline (270 mg, 1.50 mmol) and copper acetate 
monohydrate (303 mg, 1.52 mmol) was dissolved in dry DMF (5 mL) and a condenser 
attached. The reaction was stirred at 90 °C for 24 h, and then the solvent was evaporated in 
vacuo. The residue was purified as for Method 1 to give 7d as a colourless powder (44 mg, 
21%).  
Method 3 (from adenine): A mixture of adenine (4) (136.0 mg, 1.007 mmol), phenyl boronic 
acid (184.2 mg, 1.510 mmol), 1,10-phenanthroline (270.9 mg, 1.505 mmol) and anhydrous 
copper acetate (277.1 mg, 1.528 mmol) was dissolved in dry DMF (5 mL) and a condenser 
attached. The reaction was stirred at 90 °C for 24 h, and then the solvent was evaporated in 
vacuo. The residue was purified as for Method 1 to give 7d as a colourless powder (37 mg, 
17%) and 29d as an off-white powder (54 mg, small impurities, ~25%).  
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Method 4 (from 6-chloro-9-phenylpurine): 6-Chloro-9-phenylpurine (14) (115 mg, 0.499 
mmol) was dissolved in 5 mL concentrated ammonium hydroxide and heated at 100 °C in a 
sealed vial overnight. The ammonium hydroxide was evaporated in vacuo and the residue 
purified using flash chromatography (2-5% methanol in dichloromethane) to give 7d as a 
colourless powder (100 mg, 95%). 
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9-Phenyl-9H-purin-6-amine (7d) 
 
1
H NMR (DMSO-d6, 300 MHz) δ 8.57 (s, 1H, H-2), 8.21 (s, 1H, H-8), 7.89 – 7.86 (m, 2H,  
H-11), 7.59 – 7.54 (m, 2H, H-12), 7.43 – 7.40 (m, 1H, H-13), 7.38 (br s, 2H, NH2).  
13
C NMR (DMSO-d6, 75 MHz) δ 156.4 (C-6), 153.2 (C-2), 149.2 (C-4), 139.7 (C-7), 135.1 
(C-10), 129.5 (C-12), 127.4 (C-13), 123.0 (C-11), 119.3 (C-5).  
MS EI m/z (rel. %) 211 (100, M
+
), 184 (13), 104 (7), 77 (13).  
HR-MS Found 211.0855, calculated for C11H9N5 211.0858. 
M.p. 244-246 °C (lit.
94
 = 245-6 °C).  
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Spectrum 53. 1H NMR of 9-Phenyl-9H-purin-6-amine (7d). 
 
Spectrum 54. 1H NMR of 9-Phenyl-9H-purin-6-amine (7d), expansion of the aromatic region. 
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Spectrum 55. 13C NMR of 9-Phenyl-9H-purin-6-amine (7d). 
 
Spectrum 56. HMQC of 9-Phenyl-9H-purin-6-amine (7d). 
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Spectrum 57. HMBC of 9-Phenyl-9H-purin-6-amine (7d). 
 
Spectrum 58. HMBC of 9-Phenyl-9H-purin-6-amine (7d), expansion of the aromatic region. 
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7-Phenyl-7H-purin-6-amine (29d) 
 
1
H NMR (DMSO-d6, 400 MHz) δ 8.49 (s, 1H, H-8), 8.30 (s, 1H, H-2), 7.68 – 7.51 (m, 5H, 
H-11, H-12 and H-13), 6.09 (s, 2H, NH2). 
13
C NMR (DMSO-d6, 100 MHz) δ 159.9 (C-4), 152.7 (C-2), 151.1, 145.8 (C-8), 135.4  
(C-10), 129.9 (C-11 or C-12), 129.0 (C-13), 125.6 (C-11 or C-12), 110.5 (C-5). 
MS EI m/z (rel. %) 211 (100, M
+
), 157 (11), 104 (14), 77 (23). 
HR-MS Found 211.085116, calculated for C11H9N5 211.0858. 
M.p. not obtained.  
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Spectrum 59. 1H NMR of 7-Phenyl-7H-purin-6-amine (29d). 
 
Spectrum 60. 13C NMR of 7-Phenyl-7H-purin-6-amine (29d). 
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Spectrum 61. HSQC of 7-Phenyl-7H-purin-6-amine (29d). 
 
Spectrum 62. HSQC of 7-Phenyl-7H-purin-6-amine (29d), expansion of the aromatic region. 
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Spectrum 63. HMBC of 7-Phenyl-7H-purin-6-amine (29d). 
 
Spectrum 64. HMBC of 7-Phenyl-7H-purin-6-amine (29d), expansion of the aromatic region.  
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Spectrum 65. HMBC of 7-Phenyl-7H-purin-6-amine (29d), expansion of the aromatic region showing 
the coupling of H-8 to C-10. N.b. Long range 
1
H-C J coupling constant = 2 Hz. 
 
Spectrum 66. NOESY of 7-Phenyl-7H-purin-6-amine (29d). 
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9-Benzyl-8-bromo-9H-purin-6-amine (6a) and 3-Benzyl-8-bromo-3H-purin-6-amine 
(30a) 
 
Method 1: A mixture of 8-bromoadenine (5) (126 mg, 1.03 mmol), DMF (5 mL) and 
potassium carbonate (280 mg, 2.03 mmol) was stirred at ambient temperature under a 
nitrogen atmosphere for 30 minutes. Benzyl bromide (0.18 mL, 1.5 mmol) was added and the 
mixture stirred for another 4 h. The mixture was filtered and the solvent evaporated in vacuo. 
The residue was purified by column chromatography (0-5% methanol in dichloromethane) to 
give compounds 6a (45 mg, 15%) and 30a (128 mg, 42%) as colourless powders.  
Method 2: A mixture of 9-benzyladenine (7a) (193 mg, 0.857 mmol) and  
N-bromosuccinimide (497 mg, 2.79 mmol) was weighed into a flask and the system flushed 
with nitrogen gas. Dry DMF (4 mL) was added and stirred at ambient temperature for 24 h. 
The solvent was evaporated in vacuo and the residue purified by flash chromatography (1:1 
ethyl acetate: hexanes – ethyl acetate) to give 6a as a pale reddish powder (121 mg, 42%). 
Method 3: A mixture of 9-benzyladenine (7a) (147 mg, 0.653 mmol) and  
N-bromosuccinimide (601 mg, 3.38 mmol) was weighed into a flask and the system flushed 
with nitrogen gas. Chloroform (10 mL) was added and refluxed for 8 h. The crude mixture 
was washed with 2 x 10 mL saturated sodium sulfite and 2 x 10 mL saturated sodium chloride 
solutions. The solvent was evaporated in vacuo and the residue purified by flash 
chromatography (1:1 ethyl acetate:hexanes – ethyl acetate – 5-10% methanol in 
dichloromethane) to give 6a as a colourless powder (32 mg, 16%). 
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7.1.1. X-ray Crystallographic Analysis of 30a 
Crystals of 3 suitable for X-ray crystallography were obtained from a solution of compound 
30a in acetonitrile placed inside a larger vial containing ethyl acetate. They are unstable at 
room temperature due to loss of co-crystallized ethyl acetate solvent molecules, and X-ray 
data collection with Apex-2
95
 was thus performed at 105 K. Apex II single crystal CCD-
diffractometer, MoKα radiation (λ = 0.71069 Å), 0.30 x 0.30 x 0.26 mm block-shaped 
specimen, data integration and cell refinement with SAINT-Plus,
96
 absorption correction by 
SADABS,
97
 structure solution by and least-squares refinement on F
2
 with SHELXTL.
98
  
Solvent molecules are located on two different inversion centres, each with a maximum 
allowed occupancy of 0.500 and form distinct channels running through the crystal along the 
ab-diagonal. The geometries of independent solvent molecules were constrained to be similar 
within a standard deviation of 0.002 Å for bond lengths and 0.003 Å for 1-3 distances. 
3-Benzyl-8-bromo-3H-purin-6-amine ethyl acetate solvate: C12H10BrN5·0.5C4H8O2, M = 
348.21, triclinic, P-1, a = 8.4937(6) Å, b = 12.9096(9) Å, c = 15.2238(10) Å, α = 101.723(1)°, 
β = 105.162(1)°, γ = 108.192(1)°, Z = 4, Nobserved = 5830, R[F
2
 > 2σ(F2)] = 0.058, wR(F2) = 
0.146, CCDC 786213. 
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9-Benzyl-8-bromo-9H-purin-6-amine (6a) 
 
1
H NMR (DMSO-d6, 400 MHz) δ 8.16 (s, 1H, H-2), 7.47 (br s, 2H, NH2), 7.33 – 7.21 (m, 
5H, H-12, H-13 and H-14), 5.35 (s, 2H, H-10).  
13
C NMR (DMSO-d6, 150 MHz) δ 154.7 (C-6), 153.0 (C-2), 150.9 (C-4), 135.9 (C-8), 128.7 
(C-12 or C-13), 127.8 (C-14), 127.1 (C-12 or C-13), 126.5 (C-11), 119.0 (C-5), 46.6 (C-10).  
MS EI m/z (rel. %) 305/303 (26/26, M
+
), 304/302 (19/15), 224 (52), 91 (100).  
HR-MS Found 303.0112, calculated for C12H10BrN5 303.0120. 
M.p. 238 °C (lit.
34
 = 227-230 °C). 
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Spectrum 67. 1H NMR of 9-Benzyl-8-bromo-9H-purin-6-amine (6a). 
 
Spectrum 68. 13C NMR of 9-Benzyl-8-bromo-9H-purin-6-amine (6a). 
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Spectrum 69. HMQC of 9-Benzyl-8-bromo-9H-purin-6-amine (6a). 
 
Spectrum 70. HMBC of 9-Benzyl-8-bromo-9H-purin-6-amine (6a). 
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Spectrum 71. HMBC of 9-benzyl-8-bromo-9H-purin-6-amine (6a), expansion of the benzylic and 
aromatic region. 
 
145 
 
3-Benzyl-8-bromo-3H-purin-6-amine (30a) 
 
1
H NMR (DMSO-d6, 600 MHz) δ 8.53 (s, 1H, H-2), 8.24 and 8.08 (br d, 2H, NH2),  
7.39 – 7.28 (m, 5H, H-12, H-13 and H-14), 5.46 (s, 2H, H-10).  
13
C NMR (DMSO-d6, 75 MHz) δ 153.6 (C-6), 149.8 (C-4), 144.0 (C-2), 139.3 (C-8), 135.8 
(C-11), 128.7 (C-12 or C-13), 128.1 (C-14), 127.8 (C-12 or C-13), 121.5 (C-5), 52.0 (C-10).  
MS EI m/z (rel. %) 305/303 (20/20, M
+
), 304/302 (18/14), 224 (30), 91 (100), 65 (11). 
HR-MS Found 303.0125, calculated for C12H10BrN5 303.0120. 
M.p. 233-235 °C.  
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Spectrum 72. 1H NMR of 3-Benzyl-8-bromo-3H-purin-6-amine (30a). 
 
Spectrum 73. 13C NMR of 3-Benzyl-8-bromo-3H-purin-6-amine (30a) with expansion of the phenyl 
region (inset). 
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Spectrum 74. HMQC of 3-Benzyl-8-bromo-3H-purin-6-amine (30a). 
 
Spectrum 75. HMBC of 3-Benzyl-8-bromo-3H-purin-6-amine (30a). 
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Spectrum 76. 
1
H-
13
N HSQC of 3-Benzyl-8-bromo-3H-purin-6-amine (30a). 
 
Spectrum 77. 1D selective NOE of 3-Benzyl-8-bromo-3H-purin-6-amine (30a), with irradiation of 
the protons in the methylene group. 
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Spectrum 78. 1D selective NOE of 3-Benzyl-8-bromo-3H-purin-6-amine (30a), with irradiation of 
the phenyl protons closest to the methylene group. 
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9-Cyclopentyl-8-bromo-9H-purin-6-amine (6b) 
 
Method 1: A mixture of bromine (0.20 mL, 3.9 mmol) and distilled water (15 mL) was poured 
over 9-cyclopentyladenine (7b) (108 mg, 0.531 mmol) and stirred at ambient temperature for 
17 h with a condenser. The bromine and water mixture was evaporated first in the fumehood 
then in vacuo. The residue was purified by flash chromatography to give 6b as a pale reddish 
powder (hexanes – 1:1 hexanes:ethyl acetate – ethyl acetate) (95 mg, 67%).  
Method 2: LDA (2.52 mmol) in 5 mL dry THF was added dropwise to 9-cyclopentyladenine 
(7b) (103 mg, 0.507 mmol) dissolved in 10 mL dry THF at -78 °C and stirred for 1 hour 
under nitrogen atmosphere. 1,2-Dibromo-1,1,2,2-tetrachloroethane (500 mg, 3.07 mmol) in  
1 mL dry THF was added dropwise and the reaction was stirred for a further 4 h. The reaction 
was quenched with 0.50 mL saturated ammonium chloride solution and the solvents 
evaporated in vacuo. The residue was purified using flash chromatography (1-5% methanol in 
dichloromethane) to give 102 mg of a 10:3 mixture of the expected product (6b) and the  
8-chloro analogue (8b) (calculated yields from NMR = 58% and 17%, respectively). 
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9-Cyclopentyl-8-bromo-9H-purin-6-amine (6b) 
 
1
H NMR (DMSO-d6, 300 MHz) δ 8.10 (s, 1H, H-2), 7.32 (s, 2H, NH2), 4.873 (quintet,  
J = 8.4 Hz, H-10), 2.37 – 2.27 (m, 2H, H-11 and H-12), 2.25 – 1.91 (m, 4H, H-11 and H-12),  
1.90 – 1.67 (m, 2H, H-11 and H-12).  
13
C NMR (DMSO-d6, 75 MHz) δ 154.8 (C-6), 152.2 (C-2), 150.4 (C-4), 126.6 (C-8), 119.6 
(C-5), 57.8 (C-10), 30.0 (C-11 or C-12), 24.4 (C-11 or C-12).  
MS EI m/z (rel. %) 283/281 (17/17, M
+
), 242/40 (13/13), 215/213 (99/100), 202 (15), 
188/186 (16/16).  
HR-MS Found 281.0273, calculated for C10H12BrN5 281.0276. 
M.p. 186-189 °C (lit.
69
 = 193 °C).  
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Spectrum 79. 1H NMR of 9-Cyclopentyl-8-bromo-9H-purin-6-amine (6b). 
 
Spectrum 80. 13C NMR of 9-Cyclopentyl-8-bromo-9H-purin-6-amine (6b). 
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Spectrum 81. HMQC of 9-Cyclopentyl-8-bromo-9H-purin-6-amine (6b). 
 
Spectrum 82. HMQC of 9-Cyclopentyl-8-bromo-9H-purin-6-amine (6b). 
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9-(Cyclohexylmethyl)-8-bromo-9H-purin-6-amine (6c) 
 
Method 1: A mixture of 8-bromoadenine (5) (217 mg, 1.06 mmol), DMF (5 mL) and 
potassium carbonate (280 mg, 2.01 mmol) was stirred at ambient temperature under a 
nitrogen atmosphere. (Bromomethyl)cyclohexane (0.28 mL, 2.0 mmol) was added and the 
mixture stirred for 20 h. The mixture was filtered and the solvent evaporated in vacuo. The 
residue was purified by column chromatography to give 6c as a colourless powder (0-10% 
methanol in dichloromethane) (43 mg, 13%).  
Method 2: A mixture of bromine (0.20 mL, 3.9 mmol) and distilled water (15 mL) was poured 
over 9-(cyclohexylmethyl)adenine (7c) (146 mg, 0.631 mmol) and stirred at ambient 
temperature for 17 h with a condenser. The bromine and water mixture was evaporated first in 
the fumehood then in vacuo. The residue was purified by flash chromatography to give 6c as a 
pale reddish powder (0:1 – 1:0 hexanes:ethyl acetate) (126 mg, 66%). 
Method 3: LDA (2.52 mmol) in 5 mL dry THF was added dropwise to  
9-(cyclohexylmethyl)adenine (7c) (118 mg, 0.510 mmol) dissolved in 10 mL dry THF at -78 
°C and stirred for 1 hour under nitrogen atmosphere. 1,2-dibromotetrachloroethane (495 mg, 
3.04 mmol) in 1 mL dry THF was added dropwise and the reaction was stirred for a further 4 
h. The reaction was quenched with 0.50 mL saturated ammonium chloride solution and the 
solvents evaporated in vacuo. The residue was purified using flash chromatography (1-5% 
methanol in dichloromethane) to give 100 mg of a 5:2 mixture of the expected product (6c) 
and the 8-chloro analogue (8c) (calculated yields from NMR = 57% and 23%, respectively). 
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9-(Cyclohexylmethyl)-8-bromo-9H-purin-6-amine (6c) 
 
1
H NMR (DMSO-d6, 300 MHz) δ 8.11 (s, 1H, H-2), 7.35 (br s, 2H, NH2), 3.94 (d, 2H, C-10, 
J = 7.5 Hz), 1.90 (ddd, J = 10.6, 7.3, 3.4 Hz, 1H, H-11), 1.78 – 1.36 (m, 5H, H-12, H-13 and 
H-14), 1.36 – 0.91 (m, 5H, H-12, H-13 and H-14).  
13
C NMR (DMSO-d6, 75 MHz) δ 154.7 (C-6), 152.8 (C-2), 151.0 (C-4), 126.6 (C-8), 118.9 
(C-5), 49.5 (C-10), 37.3 (C-11), 30.0 (C-12), 25.7 (C-14), 25.1 (C-13).  
MS EI m/z (rel. %) 311/309 (2/2, M
+
), 231 (39), 230 (100), 227 (10), 215/213 (28/26), 148 
(40).  
HR-MS Found 309.0587, calculated for C12H16BrN5 309.0589. 
M.p. 228-230 °C.  
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Spectrum 83. 1H NMR of 9-(Cyclohexylmethyl)-8-bromo-9H-purin-6-amine (6c). 
 
Spectrum 84. 13C NMR of 9-(Cyclohexylmethyl)-8-bromo-9H-purin-6-amine (6c). 
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Spectrum 85. HMQC of 9-(Cyclohexylmethyl)-8-bromo-9H-purin-6-amine (6c). 
 
Spectrum 86. HMBC of 9-(Cyclohexylmethyl)-8-bromo-9H-purin-6-amine (6c). 
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General procedure for lithiation and subsequent halogenation of 9-substituted adenines 
Lithium diisopropylamide (LDA) was generated from n-BuLi in hexanes and dry 
diisopropylamine by cooling approximately 2.6 mmol diisopropylamine in dry THF to -78 °C 
under an inert atmosphere. n-BuLi in hexanes (approximately 2.5 mmol) was added dropwise 
and the mixture was stirred for one hour under these conditions. 
The appropriate 9-substituted adenine (0.5 mmol) was dissolved in dry THF (10 mL for 7b 
and 7c and 20 mL for 7a) and added dropwise to the LDA in 5 mL dry THF at -78 °C under 
an argon atmosphere. This reaction mixture was stirred for one hour at this temperature. The 
halogenating agent (dibromotetrachloroethane or hexachloroethane) (1.5 mmol) in 2 mL dry 
THF was added dropwise and the reaction was stirred for a further 4 h. The reaction was 
quenched with 0.50 mL saturated ammonium chloride solution and allowed to come to 
ambient temperature. 
The mixture was transferred to a separatory funnel and a further 15 mL ammonium chloride 
solution was added. The organic phase was removed and the water phase was extracted with  
3 x 15 mL ethyl acetate. The organic phases were combined and dried with 15 mL saturated 
sodium chloride solution and the solvent evaporated in vacuo. The residue was purified using 
flash chromatography (0:1 – 1:0 ethyl acetate:dichloromethane) to give compounds 8b – 8d as 
colourless powders. 
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8-Chloro-9-cyclopentyl-9H-purin-6-amine (8b) 
 
Yield 82 mg, 69% 
1
H NMR (DMSO-d6, 600 MHz) δ 8.12 (s, 1H, H-2), 7.31 (s, 2H, NH2), 4.90 (p, J = 8.6 Hz, 
1H, H-10), 2.35 – 2.17 (m, 2H, H-11 and H-12), 2.17 – 1.79 (m, 4H, H-11 and H-12),  
1.79 – 1.51 (m, 2H, H-11 and H-12). 
13
C NMR (DMSO-d6, 150 MHz) δ
 154.9 (C-6), 152.4 (C-2), 150.1 (C-4), 136.4 (C-8), 117.9 
(C-5), 56.6 (C-10), 30.0 (C-11), 24.4 (C-12). 
MS EI m/z (rel. %) 239/237 (5/15, M
+
), 202 (7), 198/196 (5/15), 171/169 (34/100), 144/142 
(7/22). 
HR-MS Found 237.0782, calculated for C10H12ClN5 237.0781. 
M.p. 181-183 °C.  
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Spectrum 87. 1H NMR of 8-Chloro-9-cyclopentyl-9H-purin-6-amine (8b). 
 
Spectrum 88. 13C APT NMR of 8-Chloro-9-cyclopentyl-9H-purin-6-amine (8b). 
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Spectrum 89. HSQC of 8-Chloro-9-cyclopentyl-9H-purin-6-amine (8b). 
 
Spectrum 90. HMBC of 8-Chloro-9-cyclopentyl-9H-purin-6-amine (8b). 
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8-Chloro-9-(cyclohexylmethyl)-9H-purin-6-amine (8c) 
 
Yield 90 mg, 68% 
1
H NMR (DMSO-d6, 400 MHz) δ 8.13 (s, 1H, H-2), 7.36 (s, 2H, NH2), 3.96 (d, J = 7.4 Hz, 
2H, H-10), 1.87 (ddd, J = 10.9, 7.4, 3.5 Hz, 1H, H-11), 1.75 – 1.30 (m, 5H, H-12, H-13 and 
H-14), 1.13 – 0.99 (m, 5H, H-12, H-13 and H-14). 
13
C NMR (DMSO-d6, 150 MHz) δ 154.8 (C-6), 152.9 (C-2), 150.6 (C-4), 136.8 (C-8), 117.4 
(C-5), 48.7 (C-10), 37.1 (C-11), 29.9 (C-12 or C-13), 25.7 (C-14), 25.0 (C-12 or C-13). 
MS EI m/z (rel. %) 267/265 (2/8, M
+
), 230 (100), 185/183 (7/21), 184/182 (8/19), 171/169 
(14/43), 148 (15), 142 (8).  
HR-MS Found 265.1098, calculated for C12H16ClN5 265.1094. 
M.p. 229-230 °C.  
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Spectrum 91. 1H NMR of 8-Chloro-9-(cyclohexylmethyl)-9H-purin-6-amine (8c). 
 
Spectrum 92. 13C APT NMR of 8-Chloro-9-(cyclohexylmethyl)-9H-purin-6-amine (8c). 
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Spectrum 93. HSQC of 8-Chloro-9-(cyclohexylmethyl)-9H-purin-6-amine (8c). 
 
Spectrum 94. HMBC of 8-Chloro-9-(cyclohexylmethyl)-9H-purin-6-amine (8c). 
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8-Chloro-9-phenyl-9H-purin-6-amine (8d) 
 
Yield 89 mg, 67% 
1
H NMR (DMSO-d6, 600 MHz) δ 8.10 (s, 1H, H-2), 7.66 – 7.52 (m, 5H, H-10, H-11 and  
H-12), 7.47 (br s, 2H, NH2). 
13
C NMR (DMSO-d6, 150 MHz) δ 155.0 (C-4 or C-6), 153.4 (C-2), 151.3 (C-4 or C-6), 136.3 
(C-8), 133.0 (C-10), 129.44 (C-13), 129.40 (C-11 or C-12), 127.8 (C-11 or C-12), 117.4  
(C-5). 
MS EI m/z (rel. %) 247/245 (36/100, M
+
), 218 (13), 183 (10), 156 (6), 103 (6), 77 (16). 
HR-MS Found 245.0469, calculated for C11H8ClN5 245.0468. 
M.p. 225-226 °C.  
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Spectrum 95. 1H NMR of 8-Chloro-9-phenyl-9H-purin-6-amine (8d). 
 
Spectrum 96. 1H NMR of 8-Chloro-9-phenyl-9H-purin-6-amine (8d), expansion of the aromatic 
region. 
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Spectrum 97. 13C NMR of 8-Chloro-9-phenyl-9H-purin-6-amine (8d), with expansion of the phenyl 
region (inset). 
 
Spectrum 98. HSQC of 8-Chloro-9-phenyl-9H-purin-6-amine (8d). 
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Spectrum 99. HMBC of 8-Chloro-9-phenyl-9H-purin-6-amine (8d). 
 
Spectrum 100. HMBC of 8-Chloro-9-phenyl-9H-purin-6-amine (8d), expansion of the aromatic 
region. 
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8-Bromo-6-chloro-9-phenyl-9H-purine (44) and By-product (45) 
 
Lithium diisopropylamide (LDA) was generated from n-BuLi in hexanes and dry 
diisopropylamine by cooling diisopropylamine (0.77 mmol) in dry THF to -78 °C under an 
inert atmosphere. n-BuLi in hexanes (0.70 mmol) was added dropwise and the mixture was 
stirred for one hour under these conditions. 
6-Chloro-9-phenylpurine (14) (110 mg, 0.481 mmol) was dissolved in 5 mL dry THF and 
added dropwise to the LDA in 5 mL dry THF at -78 °C under an argon atmosphere. This 
mixture was stirred for one hour under these conditions. This reaction mixture was stirred for 
one hour at this temperature. 1,2-Dibromo-tetrachloroethane (331 mg, 1.02 mmol) in 1 mL 
dry THF was added dropwise and the reaction was stirred for a further 2 h.  
The reaction was quenched with 0.50 mL saturated ammonium chloride solution and allowed 
to come to ambient temperature. The solvent was evaporated in vacuo and the residue was 
purified using flash chromatography (1:3 ethyl acetate:hexanes) to give 44 as a colourless 
powder (90 mg, 61%) and 15 mg of impure by-product (45). 
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8-Bromo-6-chloro-9-phenyl-9H-purine (44) 
 
1
H NMR (DMSO-d6, 600 MHz) δ 8.72 (s, 1H, H-2), 7.69 – 7.58 (m, 5H, H-11, H-12 and  
H-13). 
13
C NMR (DMSO-d6, 150 MHz) δ 153.9 (C-4 or C-6), 152.2 (C-2), 147.6 (C-4 or C-6), 135.9 
(C-8), 133.2, 131.1 (C-5), 130.2 (C-13), 129.6 (C-11 or C-12), 128.2 (C-11 or C-12). 
MS EI m/z (rel. %) 312/310/308 (24/100/77, M
+
), 231/229 (15/45), 194 (13), 167 (14), 114 
(6). 
HR-MS Found 307.9470, calculated for C11H6BrClN4 307.9464. 
M.p. 234-236 °C.  
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Spectrum 101. 1H NMR of 8-Chloro-9-phenyl-9H-purin-6-amine (44). 
 
Spectrum 102. 13C NMR of 8-Chloro-9-phenyl-9H-purin-6-amine (44). 
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Spectrum 103. HSQC of 8-Chloro-9-phenyl-9H-purin-6-amine (44). 
 
Spectrum 104. HMBC of 8-Chloro-9-phenyl-9H-purin-6-amine (44). 
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Spectrum 105. HMBC of 8-Chloro-9-phenyl-9H-purin-6-amine (44), expansion of the aromatic 
region. 
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Data for by-product obtained from bromination of 6-chloro-9-phenylpurine (45) 
Suggested structure: 
 
Possible assignment of data:  
1
H NMR (DMSO-d6, 600 MHz) δ 8.72 (s, 1H, 1 x H-2), 8.19 (s, 1H, 1 x H-2), 7.52 – 7.49 (m, 
3H, Ph-H), 7.41 – 7.29 (m, 3H, Ph-H), 7.27 (dd, J = 7.8, 1.4 Hz, 2H, Ph-H), 7.10 (d,  
J = 7.2 Hz, 2H, Ph-H), 4.19 (dp, J = 13.7, 6.8 Hz, 1H, NH, isopropyl group), 3.68 (dp,  
J = 13.4, 6.7 Hz, 1H, 1H, NH from isopropyl group), 1.17 (d, J = 6.8 Hz, 6H, 2 x methyl, 
isopropyl group), 1.05 (d, J = 6.8 Hz, 6H, 2 x methyl, isopropyl group). 
13
C NMR (DMSO-d6, 150 MHz) δ 154.13 (C-2), 153.3 (C-4 or C-6), 152.9 (C-4’ or C-6’), 
152.6 (C-2’), 149.4 (C-4’ or C-6’), 144.4*, 134.1 (C-10 or C-10’), 133.5 (C-10 or C-10’), 
131.9*, 130.2 (C-5’), 129.1 (C-12 or C-12’), 129.0 (C-13 or C-13’), 128.6 (C-12 or C-12’), 
128.4 (C-13 or C-13’), 127.3 (C-11 or C-11’), 127.0 (C-11 or C-11’), 116.9*, 97.2*, 48.2 
(CH, isopropyl group), 46.3 (CH, isopropyl group), 22.86 (methyl, isopropyl group), 19.0 
(methyl, isopropyl group). * These shifts cannot be assigned from 2D NMR correlations. 
They could be the missing peaks for C-4 or C-6, C5, C8 and C8’ or they could belong to an 
impurity. 
MS EI m/z (rel. %) 525/523 (37/100, M
+
), 482/480 (31/85), 413 (18), 262 (6), 77 (8). 
HR-MS Found 523.1993, calculated for C28H26ClN9 523.2000. 
M.p. not obtained. 
175 
 
 
Spectrum 106. 1H NMR of Unknown By-product (45). 
 
Spectrum 107. 13C NMR of Unknown By-product (45). 
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Spectrum 108. HSQC of Unknown By-product (45). 
 
Spectrum 109. HMBC of Unknown By-product (45). 
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Spectrum 110 HMBC of Unknown By-product (45), expansion of the aromatic region. 
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6-Amino-9-benzyl-7H-purin-8(9H)-one (3a) and 6-Amino-7,9-dibenzyl-7H-purin-8(9H)-
one (39a) 
 
Method 1: 9-Benzyl-8-bromoadenine (6a) (63.7 mg, 0.12 mmol) was refluxed in formic acid 
(5 mL) overnight with stirring. The formic acid was evaporated then co-evaporated with 3 x  
5 mL water and product dried in vacuo. The residue was purified by flash chromatography  
(5-10% methanol in dichloromethane) to give 3a as a colourless powder (103 mg, 85%). 
Method 2: A mixture of 8-oxoadenine (118 mg, 0.781 mmol), DMF (5 mL) and potassium 
carbonate (218 mg, 1.58 mmol) was stirred at ambient temperature under a nitrogen 
atmosphere for 15 minutes. Benzyl bromide (0.11 mL, 0.92 mmol) was added and the mixture 
stirred for another 3 h. The mixture was filtered and the solvent evaporated in vacuo. The 
residue was purified by column chromatography (5-10% methanol in dichloromethane) to 
give compounds 3a (36 mg, 19%) and 39a (78 mg, ~30%, impure).  
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6-Amino-9-benzyl-7H-purin-8(9H)-one (3a) 
 
1
H NMR (DMSO-d6, 200 MHz) δ 10.24 (s, 1H, NH), 8.01 (s, 1H, H-2), 7.66 – 6.86 (m, 5H,  
H-12, H-13 and H-14), 6.43 (s, 2H, NH2), 4.91 (s, 2H, H-10).  
13
C NMR (DMSO-d6, 75 MHz) δ 152.0 (C-8), 151.1 (C-2), 147.3 (C-4), 146.67 (C-6), 137.1 
(C-11), 128.5 (C-13), 127.39 (C-12), 127.35 (C-14), 103.3 (C-5), 42.39 (C-10).  
MS EI m/z (EI, rel. %) 242 (9), 241 (56, M
+
), 240 (13), 225 (5), 212 (13), 136 (19), 110 (6), 
91 (100). 
HR-MS Found 241.0960, calculated for C12H11N5O 241.0964. 
M.p. 265-267
 
°C.
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Spectrum 111. 1H NMR of 6-Amino-9-benzyl-7H-purin-8(9H)-one (3a).
 
 
Spectrum 112. 13C NMR of 6-Amino-9-benzyl-7H-purin-8(9H)-one (3a).
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Spectrum 113. HMQC of 6-Amino-9-benzyl-7H-purin-8(9H)-one (3a).
 
 
Spectrum 114. HMBC of 6-Amino-9-benzyl-7H-purin-8(9H)-one (3a).
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Spectrum 115. HMBC of 6-Amino-9-benzyl-7H-purin-8(9H)-one (3a), expansion of the aromatic 
region.
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6-Amino-7,9-dibenzyl-7H-purin-8(9H)-one (39a) 
 
1
H NMR (DMSO-d6, 300 MHz) δ 8.03 (s, 1H, H-2), 7.45 – 7.10 (m, 10H, H-12 to H-14 and 
H-17 to H-19), 6.54 (s, 2H, NH2), 5.26 (s, 2H, H-15), 5.00 (s, 2H, H-10). 
13
C NMR (DMSO-d6, 75 MHz) δ 152.6 (C-8), 151.1 (C-2), 147.3 (C-4), 147.1 (C-6), 137.8 
(C-16), 136.8 (C-11), 128.6, 128.5, 127.41 (C-14 or C-19), 127.39 (C-14 or C-19), 127.3  
(C-12), 126.7 (C-17), 104.2 (C-5), 44.2 (C-15), 42.9 (C-10). 
MS EI m/z (rel. %) 331 (75, M
+
), 240 (22), 91 (100). 
HR-MS Found 331.1436, calculated for C19H17N5O 331.1433. 
M.p. not obtained.
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Spectrum 116. 1H NMR of 6-Amino-7,9-dibenzyl-7H-purin-8(9H)-one (39a). 
 
Spectrum 117. 13C NMR of 6-Amino-7,9-dibenzyl-7H-purin-8(9H)-one (39a). 
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Spectrum 118. 13C NMR of 6-Amino-7,9-dibenzyl-7H-purin-8(9H)-one (39a), expansion of the 
aromatic region and part of the phenyl region (inset). 
 
Spectrum 119. HMQC of 6-Amino-7,9-dibenzyl-7H-purin-8(9H)-one (39a). 
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Spectrum 120. HMBC of 6-Amino-7,9-dibenzyl-7H-purin-8(9H)-one (39a). 
 
Spectrum 121. HMBC of 6-Amino-7,9-dibenzyl-7H-purin-8(9H)-one (39a), expansion of the 
aromatic region. 
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6-Amino-3-benzyl-3H-purin-8(7H)-one (38a) 
 
3-Benzyl-8-bromoadenine (30a) (152 mg, 0.50 mmol) was refluxed in formic acid (10 mL) 
overnight with stirring. The formic acid was evaporated then co-evaporated with 3 x 10 mL 
water and product dried in vacuo. Recrystallized from chloroform and methanol to give 38a 
as colourless crystals (40 mg, 33%). 
1
H NMR (DMSO-d6, 300 MHz) δ 9.44 (s, 1H, NH), 8.31 (s, 1H, H-2), 7.37-7.31 (m, 5H,  
H-12, H-13 and H-14), 6.71 (s, 2H, NH2), 5.30 (s, 2H, H-10).  
13
C NMR (DMSO-d6, 75 MHz) δ 163.2 (C-8), 153.2 (C-4), 141.8 (C-2), 141.3 (C-6), 136.0 
(C-11), 128.6 (C-12 or C-13), 128.0 (C-14), 127.9 (C-12 or C-13), 106.1 (C-5), 51.0 (C-10). 
MS EI m/z (rel. %) 241 (26, M
+
), 240 (10), 91 (100). 
HR-MS Found 241.0955, calculated for C12H11N5O 241.0964. 
Elem. Anal. Found C, 59.93; H, 4.30; N, 28.67. C12H11N5O requires C, 59.74; H, 4.60; N, 
29.03. 
M.p. 228-230 °C.  
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Spectrum 122. 
1
H NMR of 6-Amino-3-benzyl-3H-purin-8(7H)-one (38a). 
 
Spectrum 123. 
13
C NMR of 6-Amino-3-benzyl-3H-purin-8(7H)-one (38a). 
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Spectrum 124. 
13
C NMR of 6-Amino-3-benzyl-3H-purin-8(7H)-one (38a), expansion of aromatic and 
part of purine region. 
 
Spectrum 125. HMQC of 6-Amino-3-benzyl-3H-purin-8(7H)-one (38a). 
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Spectrum 126. HMBC of 6-Amino-3-benzyl-3H-purin-8(7H)-one (38a). 
 
Spectrum 127. HMBC of 6-Amino-3-benzyl-3H-purin-8(7H)-one (38a), expansion of purine region. 
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6-Amino-9-cyclopentyl-7H-purin-8(9H)-one (3b) and 6-Amino-7,9-dicyclopentyl-7H-
purin-8(9H)-one (39b) 
 
Method 1: 9-Cyclopentyl-8-bromoadenine (6b) (237 mg, 0.84 mmol) was refluxed in formic 
acid (20 mL) overnight with stirring. The formic acid was evaporated then co-evaporated with  
3 x 20 mL water and product dried in vacuo. The residue was purified using flash 
chromatography (0-10% methanol in dichloromethane) to give 3b as a colourless powder 
(163 mg, 89%).  
Method 2: 9-Cyclopentyl-8-chloroadenine (8b) (253 mg, 1.60 mmol) was refluxed in formic 
acid (25 mL) overnight with stirring. The formic acid was evaporated then co-evaporated with  
3 x 25 mL water and product dried in vacuo and the residue was purified as for Method 1 to 
give 3b as a colourless powder (214 mg, 92%). 
Method 3: A mixture of 8-oxoadenine (2a) (121 mg, 0.801 mmol), DMF (5 mL) and 
potassium carbonate (228 mg, 1.65 mmol) was stirred at 40 °C under a nitrogen atmosphere 
for  
15 minutes. Cyclopentyl bromide (0.10 mL, 0.96 mmol) was added and the mixture stirred for 
2 days at that temperature. The temperature was then raised to 60 °C and stirred for another  
3 days. The mixture was filtered and the solvent evaporated in vacuo and the residue was 
purified as for Method 1 to give 3b as a colourless powder (45 mg, 27%) and 39b (29 mg, 
~12%, impure).  
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6-Amino-9-cyclopentyl-7H-purin-8(9H)-one (3b) 
 
1
H NMR (DMSO-d6, 300 MHz) δ 10.14 (s, 1H, NH), δ 8.00 (s, 1H, H-2), 6.36 (s, 2H, NH2), 
4.63 (quintet, 1H, H-10, J = 12.3 Hz), 2.18 – 2.01 (m, 2H, C-11 and C-12), 1.90 – 1.81 (m, 
4H, C-11 and C-12), 1.63 – 1.60 (m, 2H, C-11 and C-12).  
13
C NMR (DMSO-d6, 100 MHz) δ 151.7 (C-8), 150.6 (C-2), 147.3 (C-4), 146.6 (C-6), 103.2 
(C-5), 52.0 (C-10), 29.0 (C-11), 24.3 (C-12). 
MS EI m/z (rel. %) 219 (21, M
+
), 178 (9), 151 (100), 124 (6).  
HR-MS Found 219.1125, calculated for C10H13N5O 219.1120. 
M.p. 220-223 °C. 
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Spectrum 128. 
1
H NMR of 6-Amino-3-benzyl-3H-purin-8(7H)-one (3b). 
 
Spectrum 129. 
13
C APT NMR of 6-Amino-3-benzyl-3H-purin-8(7H)-one (3b). 
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Spectrum 130. HMQC of 6-Amino-3-benzyl-3H-purin-8(7H)-one (3b). 
 
Spectrum 131. HMBC of 6-Amino-3-benzyl-3H-purin-8(7H)-one (3b). 
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Spectrum 132. HMBC of 6-Amino-3-benzyl-3H-purin-8(7H)-one (3b), expansion of the aromatic 
region. 
196 
 
6-Amino-7,9-dicyclopentyl-7H-purin-8(9H)-one (39b) 
Suggested structure:* 
 
1
H NMR (DMSO-d6, 200 MHz) δ 8.00 (s, 1H, H-2), 7.20 (s, 10H), 6.69 (s, 2H, NH2),  
5.50 – 5.42 (m, 1H, H-13), 4.94 – 4.62 (m, 1H, H-10), 2.37 – 1.31 (m, 16H, H-11, H-12, H-14 
and H-15). 
13
C NMR (DMSO-d6, 100 MHz) δ 153.5 (C-6 or C-8), 153.4 (C-6 or C-8), 150.3 (C-2), 149.1 
(C-4), 114.7 (C-5), 82.3 (C-13), 53.0 (C-10), 32.3, 30.1, 24.6 and 23.1 (C-11, C-12, C-14 and 
C-15). 
MS EI m/z (rel. %) 287 (13, M
+
), 219 (35), 190 (5), 178 (9), 151 (100), 124 (5). 
HR-MS Found 287.1751, calculated for C15H21N5O 287.1746. 
M.p. not obtained. 
* This structure is suggested partially on the basis that the by-product of these analogous 
reactions should be similar. It is possible, however, that the cyclopentyl group on N-7 is 
actually on N-1 or N-3, since the CH on the second side-chain does not show any correlations. 
The MS data for this compound is in accordance with a dialkylated product of this nature. 
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Spectrum 133. 
1
H NMR of 6-Amino-7,9-dicyclopentyl-7H-purin-8(9H)-one (39b). 
 
Spectrum 134. 
13
C APT NMR of 6-Amino-7,9-dicyclopentyl-7H-purin-8(9H)-one (39b), with 
expansion of the purine region. 
198 
 
 
Spectrum 135. HSQC of 6-Amino-7,9-dicyclopentyl-7H-purin-8(9H)-one (39b). 
 
Spectrum 136. HMBC of 6-Amino-7,9-dicyclopentyl-7H-purin-8(9H)-one (39b). 
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6-Amino-9-(cyclohexylmethyl)-7H-purin-8(9H)-one (3c) and 6-Amino-7,9-bis(cyclo-
hexylmethyl)-7H-purin-8(9H)-one (39c) 
 
Method 1: 9-(Cyclohexylmethyl)-8-bromoadenine (6c) (129 mg, 0.42 mmol) was refluxed in 
formic acid (10 mL) overnight with stirring. The formic acid was evaporated then co-
evaporated with 3 x 20 mL water and product dried in vacuo. The residue was purified using 
flash chromatography (3-5% methanol in dichloromethane) to give 3c as a colourless powder  
(199 mg, 78%).  
Method 2: 9-(Cyclohexylmethyl)-8-chloroadenine (8c) (180 mg, 0.678 mmol) was refluxed in 
formic acid (20 mL) overnight. The formic acid was evaporated then co-evaporated with 3 x 
20 mL water and product dried in vacuo. The residue was purified using flash 
chromatography (0-10% methanol in dichloromethane) to give 3c as a colourless powder 
(151mg, 90%) and an unknown by-product (48c) as a colourless powder (7 mg, 4%). 
Method 3: A mixture of 8-oxoadenine (2a) (128 mg, 0.847 mmol), DMF (5 mL) and 
potassium carbonate (238 mg, 1.73 mmol) was heated to 50 °C under nitrogen atmosphere. 
(Bromomethyl)cyclohexane (0.14 mL, 1.013 mmol) was added and the mixture heated to  
70 °C and stirred at this temperature for 24 h. The mixture was filtered and the solvent 
evaporated in vacuo. The residue was purified by column chromatography (2.5-10% methanol 
in dichloromethane) to give 3c as a colourless powder (51 mg, 28%) and 39c as a colourless 
powder (8 mg, ~3%, impure).  
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6-Amino-9-(cyclohexylmethyl)-7H-purin-8(9H)-one (3c) 
 
1
H NMR (DMSO-d6, 300 MHz) δ 10.11 (s, 1H, NH), δ 8.00 (s, 1H, H-2), 6.39 (s, 2H, NH2), 
3.55 (d, J = 7.3 Hz, 2H, H-10), 1.80 (ddd, J = 10.7, 7.3, 3.4 Hz, 1H, H-11), 1.63 – 1.51 (m, 
5H, H-12, H-13 and H-14), 1.32 – 0.74 (m, 5H, H-12, H-13 and H-14).  
13
C NMR (DMSO-d6, 75 MHz) δ 152.3 (C-8), 150.9 (C-2), 147.8 (C-4), 146.5 (C-6), 103.1 
(C-5), 45.1 (C-10), 36.3 (C-11), 30.1 (C-12), 25.9 (C-14), 25.1 (C-13).  
MS EI m/z (rel. %) 247 (48, M
+
), 231 (49), 165 (53), 151 (100), 136 (31).  
HR-MS Found 247.1422, calculated for C12H17N5O 247.1433. 
Elem. Anal. Found C, 58.14; H, 6.83; N, 28.27. C12H17N5O requires C, 58.28; H, 6.93; N, 
28.32. 
M.p. 287-289 °C. 
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Spectrum 137. 
1
H NMR of 6-Amino-9-(cyclohexylmethyl)-7H-purin-8(9H)-one (3c). 
 
Spectrum 138. 
13
C NMR of 6-Amino-9-(cyclohexylmethyl)-7H-purin-8(9H)-one (3c). 
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Spectrum 139. HMQC of 6-Amino-9-(cyclohexylmethyl)-7H-purin-8(9H)-one (3c). 
 
Spectrum 140. HMBC of 6-Amino-9-(cyclohexylmethyl)-7H-purin-8(9H)-one (3c). 
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Spectrum 141. HMBC of 6-Amino-9-(cyclohexylmethyl)-7H-purin-8(9H)-one (3c), expansion of the 
aromatic region. 
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6-Amino-7,9-bis(cyclohexylmethyl)-7H-purin-8(9H)-one (39c) 
 
1
H NMR (DMSO-d6, 300 MHz) δ 8.01 (s, 1H, H-2), 6.48 (s, 2H, NH2), 3.80 (d, J = 7.4 Hz, 
2H, C-10), 3.60 (d, J = 7.3 Hz, 2H, C-15), 1.92 – 1.72 (m, 2H), 1.72 – 1.34 (m, 22H), 1.04 
(dt, J = 21.7, 21.3 Hz, 21H). 
13
C NMR (DMSO-d6, 75 MHz) δ 152.8 (C-8), 150.7 (C-2), 147.5 (C-4), 146.8 (C-6), 104.3 
(C-5), 46.5 (C-15), 45.4 (C-10), 36.2, 30.7, 30.0, 29.4, 25.8, 25.14 and 25.05 (C-12 to C-14 
and C-17 to C-19). 
MS EI m/z (rel. %) 343 (100, M
+
), 261 (56), 247 (49), 232 (10), 230 (8), 164 (42), 151 (49), 
136 (7). 
HR-MS Found 343.2362, calculated for C19H29N5O 343.2372. 
M.p. not obtained. 
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Spectrum 142. 
1
H NMR of 6-Amino-7,9-bis(cyclohexylmethyl)-7H-purin-8(9H)-one (39c). 
 
Spectrum 143. 
13
C NMR of 6-Amino-7,9-bis(cyclohexylmethyl)-7H-purin-8(9H)-one (39c). 
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Spectrum 144. HMQC of 6-Amino-7,9-bis(cyclohexylmethyl)-7H-purin-8(9H)-one (39c). 
 
Spectrum 145. HMBC of 6-Amino-7,9-bis(cyclohexylmethyl)-7H-purin-8(9H)-one (39c). 
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Spectrum 146. HMBC of 6-Amino-7,9-bis(cyclohexylmethyl)-7H-purin-8(9H)-one (39c), expansion 
of the aromatic region. 
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Unknown by-product from hydrolysis of 9-(cyclohexylmethyl)-8-chloroadenine (48c) 
Suggested structure: 
 
1
H NMR (DMSO-d6, 600 MHz) δ 10.99 (br s, 1H, NH or OH), 10.34 (br s, 2H, NH or OH), 
9.32 (br s, 1H, NH or OH), 8.34 (s, 1H), 3.63 (d, J = 7.3 Hz, 2H), 1.83 (ddd, J = 11.0, 7.4,  
3.6 Hz, 1H, H-11), 1.72 – 1.49 (m, 5H, H-12, H-13 and H-14), 1.16 – 0.90 (m, 5H, H-12, H-
13 and H-14). 
13
C NMR (DMSO-d6, 150 MHz) δ 161.8 (C-15), 152.3 (C-8), 150.5 (C-4), 150.2 (C-2), 137.7 
(C-6), 106.3 (C-5), 45.3 (C-10), 36.2 (C-11), 30.0 (C-12), 25.8 (C-13), 25.1 (C-14). 
MS EI m/z (rel. %) 275 (27, M
+
), 231 (7), 193 (30), 180 (100), 165 (14), 164 (16), 152 (21), 
151 (20), 136 (7).  
HR-MS Found 275.1376, calculated for C13H17N5O2 275.1382. 
M.p. not obtained. 
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Spectrum 147. 
1
H NMR of Unknown By-product (48c). 
 
Spectrum 148. 
13
C APT NMR of Unknown By-product (48c). 
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Spectrum 149. 
13
C APT NMR of Unknown By-product (48c). Signals which give correlations and/or 
appear to be “real” signals are indicated. 
 
Spectrum 150. HSQC of Unknown By-product (48c). 
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Spectrum 151. HMBC of Unknown By-product (48c). 
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6-Chloro-9-phenyl-7H-purin-8(9H)-one (11) 
 
6-Chloro-N
4
-phenylpyrimidine-4,5-diamine (10a) (440 mg, 2.00 mmol) and carbon 
diimidazole (520 mg, 3.21 mmol) was refluxed for 6 h in dry THF (5 mL). The solvent was 
evaporated in vacuo and the residue purified using flash chromatography (0-1% methanol in 
dichloromethane) to give 11 as a colourless powder (480 mg, 97%).  
1
H NMR (DMSO-d6, 600 MHz) δ 12.30 (br s, 1H, NH), 8.41 (s, 1H, H-2), 7.66 – 7.58 (m, 
2H, H-11), 7.56 – 7.54 (m, 2H, H-12), 7.47 – 7.44 (m, 1H, H-13). 
13
C NMR (DMSO-d6, 150 MHz) δ 152.0 (C-8), 150.6 (C-4 or C-6), 150.1 (C-2), 134.9 (C-4 
or C-6), 132.4 (C-10), 128.9 (C-12), 128.1 (C-13), 126.3 (C-11), 119.9 (C-5).  
MS EI m/z (rel. %) 248/246 (32/100, M
+
), 247/245 (50/96), 103 (7), 77 (17), 51 (7).  
HR-MS Found 246.0302, calculated for C11H7ClN4O 246.0308. 
M.p. 293 °C.  
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Spectrum 152. 
1
H NMR of 6-Chloro-9-phenyl-7H-purin-8(9H)-one (11). 
 
Spectrum 153. 
1
H NMR of 6-Chloro-9-phenyl-7H-purin-8(9H)-one (11), expansion of the aromatic 
region. 
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Spectrum 154. 
13
C APT NMR of 6-Chloro-9-phenyl-7H-purin-8(9H)-one (11). 
 
Spectrum 155. HSQC of 6-Chloro-9-phenyl-7H-purin-8(9H)-one (11). 
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Spectrum 156. HMBC of 6-Chloro-9-phenyl-7H-purin-8(9H)-one (11). 
 
Spectrum 157. HMBC of 6-Chloro-9-phenyl-7H-purin-8(9H)-one (11), expansion of the aromatic 
region. 
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6-Amino-9-phenyl-7H-purin-8(9H)-one (3d), 6-((4-Methoxybenzyl)amino)-9-phenyl-7H-
purin-8(9H)-one (12) and hydrochloride salt (12.HCl) 
 
Method 1: 6-Chloro-9-phenyl-7H-purin-8(9H)-one (11) and para-methoxybenzylamine was 
refluxed in n-butanol for 24 h. The solvent was evaporated in vacuo and the residue was 
purified using flash chromatography (0-2% methanol in dichloromethane) to give 12 as a 
colourless power (345 mg, ~7% 12.HCl). The crude product was then heated in 
trifluoroacetic acid (5 mL) at 60 °C for 2 h. The acid was evaporated in vacuo and the residue 
was purified using flash chromatography (0-10% methanol in dichloromethane) to give 3d as 
a colourless powder (171 mg, 75% over two steps). It is possible to obtain pure 12 through 
recrystallization of the crude after the first step with chloroform, hexanes and ethanol with a 
yield of 52%. Its hydrochloride salt (12.HCl) can be isolated through flash chromatography in 
the second step. 
Method 2: 8-Chloro-9-phenyladenine (8d) (146 mg, 0.594 mmol) was refluxed in formic acid 
(15 mL) overnight with stirring. The formic acid was evaporated then co-evaporated with 3 x 
15 mL water and product dried in vacuo. The residue was purified using flash 
chromatography (0-10% methanol in dichloromethane) to give 3d as a colourless powder  
(98 mg, 73%) and an unknown by-product (48d) as a colourless powder (6 mg, 4%). 
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6-Amino-9-phenyl-7H-purin-8(9H)-one (3d) 
 
1
H NMR (DMSO-d6, 600 MHz) δ 10.44 (br s, 1H, NH), 8.01 (s, 1H, H-2), 7.72 – 7.56 (m, 
2H, H-11), 7.52 – 7.49 (m, 2H, H-12), 7.40 – 7.38 (m, 1H, H-13), 6.53 (br s, 2H, NH2).  
13
C NMR (DMSO-d6, 150 MHz) δ 151.56 (C-8), 151.55 (C-2), 147.589 (C-4 or C-6), 
147.582 (C-4 or C-6), 133.9 (C-10), 129.2 (C-12), 127.7 (C-13), 126.4 (C-11), 104.0 (C-5).  
MS EI m/z (rel. %) 228 (23), 227 (100, M
+
), 226 (42).  
HR-MS Found 227.0802, calculated for C11H9N5O 227.0807. 
M.p. > 300 °C (decomposed) (lit.
99
 > 300 °C, decomposed). 
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Spectrum 158. 
1
H NMR of 6-Amino-9-phenyl-7H-purin-8(9H)-one (3d). 
 
Spectrum 159. 
1
H NMR of 6-Amino-9-phenyl-7H-purin-8(9H)-one (3d), expansion of the aromatic 
region. 
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Spectrum 160. 
13
C APT NMR of 6-Amino-9-phenyl-7H-purin-8(9H)-one (3d), with expansions 
clearly showing the four signals that are close-lying. 
 
Spectrum 161. HSQC of 6-Amino-9-phenyl-7H-purin-8(9H)-one (3d). 
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Spectrum 162. HMBC of 6-Amino-9-phenyl-7H-purin-8(9H)-one (3d). 
 
Spectrum 163. HMBC of 6-Amino-9-phenyl-7H-purin-8(9H)-one (3d), expansion of the aromatic 
region. 
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6-((4-Methoxybenzyl)amino)-9-phenyl-7H-purin-8(9H)-one (12) 
  
1
H NMR (DMSO-d6, 600 MHz) δ 10.29 (s, 1H, NH), 8.11 (s, 1H, H-2), 7.60 (d, J = 7.5 Hz, 
2H, H-11), 7.51 (t, J = 7.9 Hz, 2H, H-12), 7.39 (d, J = 7.4 Hz, 1H, H-13), 7.31 (d, J = 8.6 Hz, 
2H, C-16), 6.92 (dd + br s, J = 6.8, 4.8 Hz, 3H, H-17 and NH), 4.61 (d, J = 5.6 Hz, 2H, H-14), 
3.73 (s, 3H, H-19). 
13
C NMR (DMSO-d6, 150 MHz) δ 158.5 (C-19), 151.96 (C-2), 150.94 (C-8), 146.5 (C-4), 
146.0 (C-6), 133.3 (C-10), 131.1 (C-15), 128.9 (C-16), 128.7 (C-12), 127.2 (C-13), 125.9 (C-
11), 113.9 (C-17), 103.7 (C-5), 55.1 (C-19), 43.1 (C-14).  
MS EI m/z (rel. %) 347 (45, M
+
), 227 (9), 121 (100). 
HR-MS Found 347.1382, calculated for C19H17N5O2 347.1390. 
M.p. 223-227 °C 
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Spectrum 164. 
1
H NMR of 6-((4-Methoxybenzyl)amino)-9-phenyl-7H-purin-8(9H)-one (12). 
 
Spectrum 165. 
1
H NMR of 6-((4-Methoxybenzyl)amino)-9-phenyl-7H-purin-8(9H)-one (12), 
expansion of the phenyl region. 
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Spectrum 166. 
13
C NMR of 6-((4-Methoxybenzyl)amino)-9-phenyl-7H-purin-8(9H)-one (12). 
 
Spectrum 167. 
1
H NMR of 6-((4-Methoxybenzyl)amino)-9-phenyl-7H-purin-8(9H)-one (12), 
expansion of the aromatic region with further expansion around 150.9 ppm. 
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Spectrum 168. HSQC of 6-((4-Methoxybenzyl)amino)-9-phenyl-7H-purin-8(9H)-one (12), with 
expansion of part of the phenyl region (inset). 
 
Spectrum 169. HMBC of 6-((4-Methoxybenzyl)amino)-9-phenyl-7H-purin-8(9H)-one (12). 
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Spectrum 170. HMBC of 6-((4-Methoxybenzyl)amino)-9-phenyl-7H-purin-8(9H)-one (12), 
expansion of the aromatic region. 
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Unknown By-product from hydrolysis of 8-chloro-9-phenyladenine (48d) 
Suggested structure: 
 
1
H NMR (DMSO-d6, 400 MHz) δ 10.6 and 10.4 (br d, 1.5H, OH or NH), 9.36 (br s, 0.5H, 
OH or NH), 8.34 (s, 1H, H-2), 7.70 – 7.57 (m, 2H, H-11), 7.54 (t, J = 7.7 Hz, 2H, H-12), 7.44 
(t, J = 7.3 Hz, 1H, C-13). 
13
C NMR (DMSO-d6, 150 MHz) δ 161.8 (C-8 or C-15), 151.2 (C-8 or C-15), 150.3 (C-2), 
150.1 (C-4 or C-6), 138.4 (C-4 or C-6), 132.6 (C-10), 129.0 (C-12), 128.0 (C-13), 126.4  
(C-11), 106.8 (C-5). 
MS EI m/z (rel. %) 256 (28), 255 (40, M
+
), 228 (50), 227 (100). 
HR-MS Found 255.0765, calculated for C12H9N5O2 255.0756. 
M.p. not obtained. 
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Spectrum 171. 
1
H NMR of Unknown By-product (48d). 
 
Spectrum 172. 
1
H NMR of Unknown By-product (48d), expansion of the aromatic region. 
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Spectrum 173. 
13
C NMR of Unknown By-product (48d). 
 
Spectrum 174. 
13
C APT NMR of Unknown By-product (48d). 
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Spectrum 175. HSQC of Unknown By-product (48d). 
 
Spectrum 176. HMBC of Unknown By-product (48d). 
230 
 
 
Spectrum 177. HMBC of Unknown By-product (48d), expansion of the aromatic region. 
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6-Chloro-N
4
-phenylpyrimidine-4,5-diamine (10a) and N
4
,N
6
-Diphenylpyrimidine-4,5,6-
triamine (10b)  
 
Method 1: A mixture of 4,6-dichloro-5-amino-pyrimidine (55) (333 mg, 2.03 mmol), 6 mL 
distilled water, 1 mL EtOH, and 0.1 mL conc. HCl was stirred. Aniline (0.24 mL, 2.60 mmol) 
was added. The reaction mixture was refluxed for 14 h, then 5 mL of boiling water added and 
as the mixture cooled, a beige powder precipitated out of the mixture. The precipitate was 
collected and recrystallized in 2:1 methanol:water to give 10a as pale orange needles (285 mg, 
69%).  
Method 2: A mixture of 4,6-dichloro-5-amino-pyrimidine (55) (251 mg, 1.53 mmol), aniline 
(0.18 mL, 2.00 mmol), triethylamine (0.295 mL, 2.10 mmol) and n-butanol (5 mL) was 
refluxed for 3 days. The solvent was removed in vacuo and the residue was purified using 
flash chromatography (hexanes – 1:4 ethyl acetate:hexanes – 1:2 ethyl acetate:hexanes) to 
give 10a as an off-white powder (243 mg, 68%). 
Method 3: 4,6-Dichloro-5-amino-pyrimidine (55) was heated at 130 °C with stirring in 0.95 
mL aniline for 3 h. The mixture was concentrated in vacuo and purified using flash 
chromatography (hexanes with gradient to 100% ethyl acetate, then second flash 0-6% 
methanol in dichloromethane) giving N
4
,N
6
-diphenylpyrimidine-4,5,6-triamine (10b) (14 mg, 
pure and 70 mg, impure) and its hydrochloric salt (350 mg, impure). 
232 
 
6-Chloro-N
4
-phenylpyrimidine-4,5-diamine (10a) 
 
1
H NMR (DMSO-d6, 300 MHz) δ 8.57 (br s, 1H, NH), 7.85 (s, 1H, H-2), 7.70 – 7.67 (m, 2H, 
H-8), 7.35 – 7.29 (m, 2H, H-9), 7.05 – 7.00 (m, 1H, H-10).  
13
C NMR (DMSO-d6, 75 MHz) δ 148.8 (C-4 or C-6), 144.7 (C-2), 139.7 (C-7), 138.5 (C-4 or 
C-6), 128.4 (C-9), 124.8 (C-5), 122.7 (C-10), 120.5 (C-8).  
MS EI m/z (rel. %) 222/220 (32/100, M
+
), 221/219 (41/85), 185 (11), 117 (10), 104 (31), 90 
(12), 77 (25).  
HR-MS Found 220.0509, calculated for C10H9ClN4 220.0516. 
M.p. 175 °C (lit.
52
 = 175-176 °C). 
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Spectrum 178. 
1
H NMR of 6-Chloro-N
4
-phenylpyrimidine-4,5-diamine (10a). 
 
Spectrum 179. 
13
C NMR of 6-Chloro- N
4
-phenylpyrimidine-4,5-diamine (10a). 
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Spectrum 180. HMQC of 6-Chloro- N
4
-phenylpyrimidine-4,5-diamine (10a). 
 
Spectrum 181. HMBC of 6-Chloro- N
4
-phenylpyrimidine-4,5-diamine (10a). 
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Spectrum 182. HMBC of 6-Chloro-N
4
-phenylpyrimidine-4,5-diamine (10a), expansion of the 
aromatic region. 
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N
4
,N
6
-Diphenylpyrimidine-4,5,6-triamine (10b) 
 
1
H NMR (DMSO-d6, 300 MHz) δ 8.08 (s, 2H, NH2), 7.90 (s, 1H, CH), 7.64 (d, J = 7.7 Hz, 
4H, H-8), 7.26 (t, J = 7.9 Hz, 4H, H-9), 6.91 (t, J = 7.3 Hz, 2H, H-10), 4.63 (br s, 2H, NH).  
13
C NMR (DMSO-d6, 75 MHz) δ 148.0 (C-4 and C-6), 146.0 (C-2), 141.2 (C-7), 128.4 (C-9), 
121.0 (C-10), 119.4 (C-8), 110.8 (C-5). 
MS EI m/z (rel. %) 277 (100, M
+
), 146 (6), 119 (7), 104 (9), 77 (15), 71 (7). 
HR-MS Found 277.1317, calculated for C16H15N5 277.1327. 
M.p. not obtained. 
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Spectrum 183. 
1
H NMR of N
4
,N
6
-Diphenylpyrimidine-4,5,6-triamine (10b). 
 
Spectrum 184. 
13
C NMR of N
4
,N
6
-Diphenylpyrimidine-4,5,6-triamine (10b). 
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Spectrum 185. HMQC of N
4
,N
6
-Diphenylpyrimidine-4,5,6-triamine (10b). 
 
Spectrum 186. HMQC of N
4
,N
6
-Diphenylpyrimidine-4,5,6-triamine (10b), expansion of the phenyl 
region. 
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Spectrum 187. HMQC of N
4
,N
6
-Diphenylpyrimidine-4,5,6-triamine (10b). 
 
Spectrum 188. HMQC of N
4
,N
6
-diphenylpyrimidine-4,5,6-triamine (10b), expansion of the aromatic 
region. 
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Mixture of products from amination of 8-bromo-6-chloro-9-phenylpurine (6d and 46) 
 
8-Bromo-6-chloro-9-phenylpurine (120 mg, 0.388 mmol) was heated in concentrated 
ammonium hydroxide solution in a sealed vial at 100 ˚C for 17 h. The ammonium hydroxide 
was removed in vacuo and the residue purified via flash chromatography (0 – 10% methanol 
in dichloromethane) to give 50 mg of a 1:1 mixture of 6d and 46. Suggested assignments for 
NMR data are included below. 
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8-Bromo-9-phenyl-9H-purin-6-amine (6d) 
1
H NMR (DMSO-d6, 600 MHz) δ, 8.06 (s, 1H, H-2), 7.67 – 7.50 (m, 5H, H-11 to H-13), 7.47 
(s, 2H, NH2). 
13
C NMR (DMSO-d6, 150 MHz) δ 154.9 (C-6), 153.30 (C-2), 151.8 (C-4), 133.8 (C-10), 
129.4 (C-13), 129.3 (C-11 or C-12), 128.1 (C-11 or C-12), 126.40 (C-8), 118.9 (C-5). 
MS ESI 290.0 (M+H)
+
. 
HR-MS Found 288.9963, calculated for C11H8N5Br 288.9963. 
 
6-Chloro-9-phenyl-9H-purin-8-amine (46) 
1
H NMR (DMSO-d6, 600 MHz) δ 8.25 (s, 1H, H-2), 7.67 – 7.50 (m, 5H, H-11 to H-13), 7.26 
(s, 2H, NH2). 
13
C NMR (DMSO-d6, 150 MHz) δ 156.0 (C-8), 147.5 (C-2), 131.6 (C-5), 140.2 (C-4 or C-6), 
153.8 (C-4 or C-6), 132.4 (C-10), 129.7 (C-11 or C-12), 129.2 (C-13), 127.4 (C-11 or C-12).  
MS ESI 246.0 (M+H)
+
. 
HR-MS Found 245.0474, calculated for C11H8N5Cl 277.1327. 
MS EI m/z (rel. %) for the mixture: 291/289 (98/100, M
+
 for 6d), 247/245 (78/23, M
+
 for 46), 
210 (32), 183 (34), 156 (14), 104 (7), 77 (38). 
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Spectrum 189. 
1
H NMR of the mixture of 8-bromo-9-phenyl-9H-purin-6-amine (6d) and 6-chloro-9-
phenyl-9H-purin-8-amine (46). 
 
Spectrum 190. 
1
H NMR of the mixture of 6d and 46, expansion of aromatic region. 
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Spectrum 191. 
13
C NMR of the mixture of 6d and 46. 
 
Spectrum 192. 
13
C NMR of the mixture of 6d and 46, expansion of aromatic region. 
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Spectrum 193. HSQC of the mixture of 6d and 46. 
 
Spectrum 194. HMBC of the mixture of 6d and 46. 
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Spectrum 195. HMBC of the mixture of 6d and 46, expansion of the aromatic region. 
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CHAPTER 8 
8. APPENDICES 
8.1. Appendix 1 
Paper I: 
 NMR and X-ray Structural Studies on 3-Benzyl-8-bromoadenine. 
H.-S. M. Siah, C. H. Gorbitz, L.-L. Gundersen, Journal of Heterocyclic Chemistry 
2011. Author proof. 
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8.2. Appendix 2 
Viruses for which the four target molecules, 3- and 9-benzyl-8-bromoadenine and 3-benzyl-8-
oxoadenine were tested against: 
 anti-feline corona virus (FIPV) and anti-feline herpes virus activity and cytotoxicity in 
CRFK cell cultures; 
 antiviral activity and cytotoxicity in: HEL cells, HeLa cells, and Vero cells; 
 anti-influenza virus activity and cytotoxicity in: MDCK cells; 
 anti-HIV activity and cytotoxicity in: MT-4 cells; 
 against cytomegalovirus in human embryonic lung (HEL) cells; and  
 against varicella-zoster virus (VZV) in human embryonic lung (HEL) cells. 
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